Polymer conjugates of mutated neublastin

ABSTRACT

A dimer comprising a mutated neublastin polypeptide coupled to a polymer is disclosed. Such dimers exhibit prolonged bioavailability and, in preferred embodiments, prolonged biological activity relative to wild-type forms of neublastin.

CROSS REFERENCE TO RELATED APPLICATIONS

This application claims priority from International applicationPCT/US02/02319, filed Jan. 25, 2002, which claims priority from U.S.provisional application Ser. No. 60/266,071, filed Feb. 1, 2001(abandoned).

FIELD OF THE INVENTION

The invention relates to protein chemistry, molecular biology,neurobiology, neurology, and pain management.

BACKGROUND OF THE INVENTION

Neurotrophic factors are naturally-occurring proteins that regulateneuronal survival during development and regulate plasticity andstructural integrity of the adult nervous system. Neurotrophic factorscan be isolated from neural tissue and from non-neural tissue. Duringthe last twenty years, many neurotrophic factors have been discovered.These neurotrophic factors can be classified into superfamilies,families, subfamilies and individual species based on their structureand function.

Neurotrophic factor superfamilies include the fibroblast growth factor(FGF) superfamily, the neurotrophin superfamily, and the transforminggrowth factor-β (TGF-β) superfamily. The glial cell line-derivedneurotrophic factor (GDNF)-related ligands are a family of proteinswithin the TGF-β superfamily. GDNF-related ligands include GDNF,persephin (PSP), neurturin (NTN) and neublastin (NBN; known as arteminor enovin). Members of the GDNF-related ligand family are distinguishedby, among other things, their seven conserved cysteine residues. Theseresidues form intramolecular and intermolecular disulfide bridges andgive rise to the tertiary and quaternary structure of the dimerizedpolypeptide ligand. Members of the family also share the ability toinduce signaling through a multicomponent receptor complex consisting ofa glycosylphosphatidylinositol (GPI)-anchored co-receptor of the GFRαfamily, a member of the GDNF-related ligand subfamily, and the RETtyrosine kinase receptor.

Activated RET initiates a signal transduction cascade that isresponsible, at least in part, for the downstream effects ofGDNF-related ligands. Accordingly, activation of RET may represent onedesirable aspect of a therapy which acts through a GFRα receptor pathwayto affect downstream cellular processes.

Neublastin is classified within the GDNF family because it sharesregions of homology with other GDNF ligands including the seven cysteinemotif (e.g., as described in EP02/02691, PCT publications US02/02319 andUS02/06388), and because of its ability to bind to, and activate, theRET receptor as part of a GFRα complex. Specifically, neublastin ishighly selective for binding to the GFRα3-RET receptor complex. In thatrespect, neublastin contains unique sub regions in its amino acidsequence as compared with other members of the GDNF-related ligandfamily.

Current data suggest that neublastin may have a protective andregenerative role in the peripheral and central nervous systems and, asa result, may be useful as a therapeutic agent for neurodegenerativedisorders. For example, data suggest that neublastin may have survivalpromoting effects on cultured sensory neurons from dorsal root gangliaand from trigeminal ganglia, and on cultured substantia nigradopaminergic neurons (Baloh et al., Neuron 21: 1291-1302 (1998)). Ittherefore appears that neublastin may promote survival of neuronalpopulations including sensory and dopaminergic neurons. This isimportant because the degeneration and dysfunction of neurons has beenassociated with disease states. For example, sensory and dopaminergicneuron pathologies underlie peripheral neuropathy and Parkinson'sdisease, respectively.

Therefore, administration of neublastin may be useful, for example, inthe treatment of diseases associated with neuronal degeneration anddysfunction. However, neublastin is rapidly cleared by the body, whichmay affect the neublastin dosing paradigm required in therapeuticapplications. Thus, a need exists for modified neublastin polypeptideswith enhanced bioavailability. Accordingly, it is an object of thepresent invention to identify modified forms of neublastin which exhibitenhanced bioavailability.

SUMMARY OF THE INVENTION

The invention provides polymer-conjugated, mutated neublastin dimers.Each dimer contains a first polypeptide comprising a firstamino-terminal amino acid and a second polypeptide comprising a secondamino-terminal amino acid. Each polypeptide individually contains: (a)an amino acid sequence characterized by at least 70%, 80%, 90%, or 95%sequence identity with amino acids 8-113 of SEQ ID NO:1; (b) a cysteineresidue at each of positions 16, 43, 47, 80, 81, 109, and 111 (numberingaccording to SEQ ID NO:1); (c) amino acid residues as follows: C atposition 16, L at position 18, V at position 25, L at position 28, G atposition 29, L at position 30, G at position 31, E at position 36, F atposition 40, R at position 41, F at position 42, C at position 43, G atposition 45, C at position 47, C at position 80, C at position 81, R atposition 82, P at position 83, F at position 91, D at position 93, S atposition 105, A at position 106, C at position 109 and C at position111; and (d) an LGLG repeat (residues 28-31 of SEQ ID NO:1), an FRFCmotif (residues 40-43 of SEQ ID NO:1), a QPCCRP motif (residues 78-83 ofSEQ ID NO:1), and a SATACGC motif (residues 105-111 of SEQ ID NO:1). Thedimer includes at least one amino acid substitution (with respect to SEQID NO:1), which provides an internal polymer conjugation site to which apolymer is conjugated.

The invention also provides a polymer-conjugated, mutated neublastindimer containing a first polypeptide and a second polypeptide, whereineach polypeptide contains 90-140, e.g., 95-120 or 100-110, amino acidsof SEQ ID NO:6 with 1-6 amino acid substitutions, each substitutionproviding a polymer conjugation site to which a polymer is conjugated.Specific examples of polypeptides of the invention include NBN113 (SEQID NO:2), NBN140 (SEQ ID NO:6), NBN116 (SEQ ID NO:7), NBN112 (SEQ IDNO:8), NBN111 (SEQ ID NO:9), NBN110 (SEQ ID NO:10), NBN109 (SEQ IDNO:11), NBN108 (SEQ ID NO:12), NBN107 (SEQ ID NO:13), NBN106 (SEQ IDNO:14), NBN105 (SEQ ID NO:15), NBN104 (SEQ ID NO:16), NBN103 (SEQ IDNO:17), NBN102 (SEQ ID NO:18), NBN101 (SEQ ID NO:19), NBN100 (SEQ IDNO:20) and NBN99 (SEQ ID NO:21).

Preferably, at least one of the two amino-terminal amino acids in thedimer is conjugated to a polymer. Preferred amino acid substitutionsinclude replacement of an arginine residue with a lysine residue (Raa#K;where aa# is the amino acid number based on SEQ ID NO: 1), andreplacement of an asparagine residue with a lysine residue (Naa#K) or anaspartate residue (Naa#D). Specific examples of such substitution areR14K, R39K, R68K, N95D, and N95K (numbering based on SEQ ID NO:1). Aparticularly preferred substitution is N95K.

Preferably, the total combined molecular weight of the polymers on adimer is 20,000-40,000 Da. Preferably, the average molecular weight ofeach polymer is 2,000-100,000 Da; more preferably, 5,000-50,000 Da; andmost preferably, about 10,000 to 20,000 Da. The polymer can be linear orbranched. Preferably, the polymer is a polyalkylene glycol moiety, e.g.,a polyethylene glycol (PEG) moiety. In some embodiments, at least onepolypeptide is glycosylated.

In some embodiments of the invention, the polymer-conjugated dimercontains a first polypeptide and a second polypeptide, wherein: (a) eachpolypeptide individually comprises 100 to 110 amino acids of SEQ IDNO:1, (b) each polypeptide comprises an asparagine-to-lysinesubstitution at amino acid number 95 in SEQ ID NO: 1, (c) and the dimercomprises 3 or 4 PEG moieties, wherein the molecular weight of each PEGmoiety is about 10,000 Da, and each PEG moiety is conjugated at anamino-terminus or at lysine 95. A preferred embodiment is a homodimercontaining a pair of monomers designated 3(,4)×10 kDa PEG NBN106-N95K.

The invention includes a pharmaceutical composition comprising a dimeraccording to the invention. In some embodiments, the compositioncontains two or more different dimers according to the invention.

The invention includes a nucleic acid, e.g., a DNA expression vectorthat encodes a polypeptide for incorporation into a dimer of theinvention. The invention also includes a host cell transformed with thenucleic acid.

The invention includes a method for treating neuropathic pain in amammal. The method includes administering to the mammal atherapeutically effective amount of the dimer of the invention. In someembodiments, the therapeutically effective amount is from 0.1 μg/kg to1000 μg/kg, from 1 μg/kg to 100 μg/kg, or from 1 μg/kg to 30 μg/kg.Administration of the dimer can be by various routes, e.g.,intramuscular, subcutaneous or intravenous. In some methods according tothe invention, the dimer is administered three times per week. Theinvention also provides a method of activating the RET receptor in amammal. The method includes administering to the mammal an effectiveamount of the dimer.

Other features and advantages of the invention will be apparent from thefollowing detailed description and claims.

DETAILED DESCRIPTION OF THE INVENTION

Unless otherwise stated, any reference to a neublastin amino acidposition number will refer to the numbering illustrated in SEQ ID NO:1.

Unless otherwise defined, all technical and scientific terms used hereinhave the same meaning as commonly understood by one of ordinary skill inthe art to which this invention belongs. Although methods and materialssimilar or equivalent to those described herein can be used in thepractice or testing of the invention, suitable methods and materials aredescribed below. All publications, patent applications, patents, andother references mentioned herein are incorporated by reference in theirentirety. In the case of conflict, the present specification, includingdefinitions, will control. In addition, the materials, methods, andexamples are illustrative only and not intended to be limiting.

As used herein, “wild-type neublastin polypeptide” means anaturally-occurring neublastin polypeptide sequence. A wild-typeneublastin polypeptide may be further defined by the source of theneublastin, for example, human, mouse, or rat neublastin (see, e.g., SEQID NO: 2, 3, or 4). A consensus neublastin polypeptide sequence isprovided as SEQ ID NO:1.

As used herein, “mutated neublastin polypeptide,” means a polypeptidethat contains at least a specified minimum level of sequence identitywith respect to a wild-type neublastin polypeptide, contains at leastone amino acid substitution, insertion or fusion, with respect to thewild-type neublastin polypeptide, and displays neublastin activity(e.g., as described in International application No. PCT/US02/02319 (WO02/060929).)

As used herein, “internal polymer conjugation site” means a non-terminalamino acid residue in a mutated neublastin polypeptide, which residueprovides a side chain suitable for conjugation of a polymer.

As used herein, “modified neublastin polypeptide,” means a polypeptidethat contains at least one attached polymer.

As used herein, “fusion” means a co-linear, covalent linkage of two ormore polypeptides through their respective peptide backbones throughgenetic expression of a polynucleotide molecule encoding those proteinsin the same reading frame.

As used herein, “identity” refers to the sequence similarity between twopolypeptides, molecules or between two nucleic acids. When a position inboth of the two compared sequences is occupied by the same base or aminoacid monomer subunit (for instance, if a position in each of the two DNAmolecules is occupied by adenine, or a position in each of twopolypeptides is occupied by a lysine), then the respective molecules arehomologous at that position. The “percentage identity” between twosequences is a function of the number of matching positions shared bythe two sequences divided by the number of positions compared ×100. Forinstance, if 6 of 10 positions in two sequences are matched, then thetwo sequences have 60% identity. By way of example, the DNA sequencesCTGACT and CAGGTT share 50% homology (3 of the 6 total positions arematched). Generally, a comparison is made when two sequences are alignedto give maximum homology. Such alignment can be provided using, forinstance, the method of Needleman et al., J. Mol Biol. 48: 443-453(1970), implemented conveniently by computer programs such as the Alignprogram (DNAstar, Inc.). “Similar” sequences are those which, whenaligned, share identical and similar amino acid residues, where similarresidues are conservative substitutions for, or “allowed pointmutations” of, corresponding amino acid residues in an aligned referencesequence. In this regard, a “conservative substitution” of a residue ina reference sequence is a substitution by a residue that is physicallyor functionally similar to the corresponding reference residue, e.g.,that has a similar size, shape, electric charge, chemical properties,including the ability to form covalent or hydrogen bonds, or the like.Thus, a “conservative substitution mutated” sequence is one that differsfrom a reference sequence or a wild-type sequence in that one or moreconservative substitutions or allowed point mutations are present. The“percentage positive” between two sequences is a function of the numberof positions that contain matching residues or conservativesubstitutions shared by the two sequences divided by the number ofpositions compared ×100. For instance, if 6 of 10 positions in twosequences are matched and 2 of 10 positions contain conservativesubstitutions, then the two sequences have 80% positive homology.

Mutated Neublastin Polypeptides

The mutated neublastin polypeptides of the invention retain neurotrophicactivity and have enhanced bioavailability as compared to the wild-typeneublastin polypeptide. For example, the mutated neublastins of thisinvention activate the RET gene product in assays in which the wild-typeneublastin activates RET. In general, the mutated neublastin polypeptidewill retain at least one of the following features but will additionallycomprise at least one modification, such that an internal polymerconjugation site is created:

-   -   i) seven conserved cysteine residues at positions 16, 43, 47,        80, 81, 109, and 111 when numbered in accordance with SEQ ID        NO:1-4;    -   ii) amino acid residues as follows: C at position 16, L at        position 18, V at position 25, L at position 28, G at position        29, L at position 30, G at position 31, E at position 36, F at        position 40, R at position 41, F at position 42, C at position        43, G at position 45, Cat position 47, C at position 80, C at        position 81, R at position 82, P at position 83, F at position        91, D at position 93, S at position 105, A at position 106, C at        position 109 and C at position 111, each when numbered in        accordance with SEQ ID NO:1-4;    -   iii) an LGLG repeat (residues 28-31 of SEQ ID NO:1), an FRFC        motif (residues 40-43 of SEQ ID NO:1), a QPCCRP motif (residues        78-83 of SEQ ID NO:1), and a SATACGC motif (residues 105-111 of        SEQ ID NO:1).

In some embodiments, the invention provides a truncated mutatedneublastin polypeptide, wherein the amino terminus of the truncatedneublastin polypeptide lacks one or more amino-terminal amino acids of amature neublastin polypeptide but is mutated to possess an internalpolymer attachment. Preferably, the truncated mutated neublastinpolypeptide, when dimerized, activates a RET polypeptide. In someembodiments the mutated neublastin polypeptide induces dimerization ofthe RET polypeptide. Such induction may require additional polypeptidesor co-factors, as would be apparent to one of skill in the art.

Amino acid sequences of human and mouse neublastin polypeptides aredisclosed in PCT publication WO00/01815. Examples of wild-typeneublastin polypeptides according to the invention are presented inTable 1A. A neublastin consensus sequence (consensus with respect tohuman, mouse and rat) is set forth in Table 1B.

TABLE 1A Wild-type mature NBN113 polypeptides

In some embodiments, at least one of the arginine (Arg or R) orasparagine (Asn or N) residues shown in bold in Table 1A is substitutedwith a different amino acid residue. In a preferred embodiment, themutated neublastin polypeptide has a lysine (Lys or K) residuesubstituted for the asparagine at amino acid position 95, indicated byan asterisk in Table 1A, and is referred to as NBN-N95K. In general, theN95K substitution results in improved solubility. This facilitatesformulation at high concentrations.

TABLE 1B NBN113 Consensus Sequence Consensus sequence: Ala Gly Xaa1 Xaa2Xaa3 Ser Arg Ala Arg Xaa4 Xaa5 Xaa6 Ala Arg Gly Cys (SEQ ID NO: 1) ArgLeu Arg Ser Gln Leu Val Pro Val Xaa7 Ala Leu Gly Leu Gly His Xaa8 SerAsp Glu Leu Xaa9 Arg Phe Arg Phe Cys Ser Gly Ser Cys Arg Arg Ala Arg SerXaa10 His Asp Leu Ser Leu Ala Ser Leu Leu Gly Ala Gly Ala Leu Arg Xaa11Pro Pro Gly Ser Arg Pro Xaa12 Ser Gln Pro Cys Cys Arg Pro Thr Arg TyrGlu Ala Val Ser Phe Met Asp Val Asn Ser Thr Trp Arg Thr Val Asp Xaa13Leu Ser Ala Thr Ala Cys Gly Cys Leu Gly wherein: Xaa₁ is Gly or Thr Xaa₆is Gly or Asp Xaa₁₁ is Pro or Ser Xaa₂ is Pro or Arg Xaa₇ is Arg or SerXaa₁₂ is Val or Ile Xaa₃ is Gly or Ser Xaa₈ is Arg or Ser Xaa₁₃ is Argor His Xaa₄ is Ala or Thr Xaa₉ is Val or Ile Xaa₅ is Ala or Thr Xaa₁₀ isPro or Gln

The invention includes a polymer-conjugated mutated neublastinpolypeptide comprising an amino acid sequence that is, for example, atleast 70% identical to amino acids 8-113 of SEQ ID NO:1 (also shown inTable 1). In one embodiment, one or more of the arginines at position14, position 39, position 68, or the asparagine at position 95 isreplaced by an amino acid other than arginine or asparagine. In oneembodiment, the wild-type amino acid is substituted with lysine orcysteine.

The substituted residues in the mutated neublastin polypeptide can bechosen to facilitate coupling of a polymer, e.g., a polyalkylene glycolpolymer, at the substituted amino acid. Advantageous sites ofmodification are those at solvent accessible regions in the neublastinpolypeptide. Such sites can be chosen based on inspection of the crystalstructure of the related neurotrophic factor, such as GDNF, whosecrystal structure is described in Eigenbrot et al., Nat. Struct. Biol.4:435-38, 1997. Sites also can be chosen based on the crystal structureof neublastin, whose crystallization and structure determination isdescribed below. Also, sites can be chosen based onstructural-functional information provided for persephin/neublastinchimeric proteins. These chimeras are described in Baloh et al., J.Biol. Chem. 275:3412-20, 2000. An exemplary listing of solventaccessible or surface exposed neublastin amino acids identified throughthis methodology is set forth in Table 2.

Table 2 provides a list of residues and numbers in human neublastin thatare expected to be surface exposed. The first column refers to surfaceexposed residues determined by examining the structure of the rat GDNFdimer formed by chains A and B (PDB code 1AGQ) and determining whether aresidue was on the surface of the structure. This structure was thencompared to a sequence alignment of GDNF and neublastin in Baloh et al.,Neuron 21:1291-1302, 1998 to determine the proper residues inneublastin. The second and third columns, respectively, refer to thesurface exposed residues determined by examining the structure of thehuman neublastin dimer formed by chains A and B. The numbering scheme inTable 2 is that shown in Table 1.

TABLE 2 1 Ala nnn 2 Gly nnn 3 Gly nnn 4 Pro nnn 5 Gly nnn 6 Ser nnn 7Arg nnn 8 Ala nnn 9 Arg nnn 10 Ala nnn 11 Ala nnn 12 Gly +nn 13 Ala −nn14 Arg ++n 15 Gly +−+ 16 Cys −−− 17 Arg +++ 18 Leu +++ 19 Arg +−− 20 Ser+++ 21 Gln +−+ 22 Leu +++ 23 Val −−− 24 Pro +−+ 25 Val −−− 26 Arg +++ 27Ala +−− 28 Leu −−− 29 Gly +++ 30 Leu +++ 31 Gly +++ 32 His +−+ 33 Arg+++ 34 Ser −−− 35 Asp +++ 36 Glu +++ 37 Leu +++ 38 Val −−− 39 Arg +++ 40Phe −−− 41 Arg +++ 42 Phe +−− 43 Cys −−− 44 Ser +−− 45 Gly +−− 46 Ser+−+ 47 Cys −−− 48 Arg +++ 49 Arg +++ 50 Ala −++ 51 Arg +−+ 52 Ser +++ 53Pro +++ 54 His −−− 55 Asp −−− 56 Leu +++ 57 Ser −−− 58 Leu −−− 59 Ala+−− 60 Ser +−+ 61 Leu −−− 62 Leu +++ 63 Gly +++ 64 Ala +++ 65 Gly +++ 66Ala +++ 67 Leu −−− 68 Arg n++ 69 Pro n++ 70 Pro n−− 71 Pro n++ 72 Gly+++ 73 Ser +++ 74 Arg n++ 75 Pro n−− 76 Val −++ 77 Ser −−− 78 Gln +++ 79Pro −−− 80 Cys −−− 81 Cys −−− 82 Arg −−− 83 Pro −−− 84 Thr +++ 85 Arg+++ 86 Tyr +++ 87 Glu +++ 88 Ala +++ 89 Val +−− 90 Ser +++ 91 Phe −−− 92Met +++ 93 Asp +−− 94 Val +++ 95 Asn +++ 96 Ser +++ 97 Thr +++ 98 Trp+++ 99 Arg +++ 100 Thr +++ 101 Val −++ 102 Asp +++ 103 Arg +++ 104 Leu−−− 105 Ser −−− 106 Ala −−− 107 Thr +++ 108 Ala +++ 109 Cys −−− 110 Gly+−− 111 Cys −−− 112 Leu +++ 113 Gly n− n indicates that the residues arenot present in the structures of GDNF or neublastin. This is eitherbecause of construct design, flexible regions, or inserts in neublastinrelative to GDNF (residues 68-71). − indicates the residues are buriedand not on the surface or are cysteine residues involved in disulfidebonds. As this protein is a cysteine knot, a great majority of theresidues are on the surface. + indicates that this residue is surfaceexposed in the GDNF structure or in the neublastin structure, althoughthe loop containing residues 66-75 is visible in only one of the GDNFmonomers (presumably flexible). This loop also contains a 4 residueinsert in neublastin relative to GDNF.

Insome embodiments, the neublastin polypeptide retains the sevenconserved Cys residues that are characteristic of the GDNF subfamily andof the TGF-beta super family.

The sequence of the human full-length prepro NBN polypeptide (SEQ IDNO:5) is shown in Table 3. Three mature forms of neublastin polypeptideswere identified. These forms include:

-   -   (i) the 140 AA polypeptide designated herein as NBN140, which        possesses the amino acid sequence designated as SEQ ID NO:6;    -   (ii) the 116 AA polypeptide designated herein as NBN116, which        possesses the amino acid sequence designated as SEQ ID NO:7; and    -   (iii) the 113 AA polypeptide designated herein as NBN113, which        possesses the amino acid sequence designated as SEQ ID NO:2.

Table 3 illustrates the relationship between the disclosed preproneublastin polypeptide sequences of the invention. Line 1 provides thepolypeptide of SEQ ID NO:5, line 2 provides the polypeptide of SEQ IDNO:6, line 3 provides the polypeptide of SEQ ID NO:7 and line 4 providesthe polypeptide of SEQ ID NO:2. The seven conserved cysteine residuesare designated by symbols (“*”, “#”, “+” and “|”) to indicate theintramolecular (* with *, # with #, and + with +) and intermolecular(“|”) disulfide bridges formed in the mature dimerized neublastinligand. The caret mark (“|”) indicates the asparagine residue at aminoacid position 95 that is substituted with a lysine in NBN106-N95K.

In alternative embodiments, the sequence of the above identifiedneublastin polypeptides have been truncated at their amino-terminalamino acid sequence. Examples of these include:

-   -   (iv) the 112AA polypeptide sequence designated herein as NBN112,        which possesses the 112 carboxy terminal amino acids of a        neublastin polypeptide, e.g., amino acids 29-140 of SEQ ID NO:6        (SEQ ID NO:8) or amino acids 2-113 of SEQ ID NOs:1, 3, or 4.    -   (v) the 111 AA polypeptide sequence designated herein as NBN111,        which possesses the 111 carboxy terminal amino acids of a        neublastin polypeptide, e.g., amino acids 30-140 of SEQ ID NO:6        (SEQ ID NO:9) or amino acids 3-113 of SEQ ID NOs:1, 3 or 4.    -   (vi) the 110AA polypeptide sequence designated herein as NBN110,        which possesses the 110 carboxy terminal amino acids of a        neublastin polypeptide, e.g., amino acids 31-140 of SEQ ID NO:6        (SEQ ID NO:10) or amino acids 4-113 of SEQ ID NOs:1, 3 or 4.    -   (vii) the 109AA polypeptide sequence designated herein as        NBN109, which possesses the 109 carboxy terminal amino acids of        a neublastin polypeptide, e.g., amino acids 32-140 of SEQ ID        NO:6 (SEQ ID NO: 11) or amino acids 5-113 of SEQ ID NOs:1, 3 or        4.    -   (viii) the 108AA polypeptide sequence designated herein as        NBN108, which possesses the 108 carboxy terminal amino acids of        a neublastin polypeptide, e.g., amino acids 33-140 of SEQ ID        NO:6 (SEQ ID NO:12) or amino acids 6-113 of SEQ ID NOs:1, 3 or        4.    -   (ix) the 107AA polypeptide sequence designated herein as NBN107,        which possesses the 107 carboxy terminal amino acids of a        neublastin polypeptide, e.g., amino acids 34-140 of SEQ ID NO:6        (SEQ ID NO:13) or amino acids 7-113 of SEQ ID NOs:1, 3 or 4.    -   (x) the 106AA polypeptide sequence designated herein        alternatively as NBN106 or N-7, which possesses the 106 carboxy        terminal amino acids of a neublastin polypeptide, e.g., amino        acids 35-140 of SEQ ID NO:6 (SEQ ID NO:14) or amino acids 8-113        of SEQ ID NOs:1, 3 or 4.    -   (xi) the 105AA polypeptide sequence designated herein as NBN105,        which possesses the 105 carboxy terminal amino acids of a        neublastin polypeptide, e.g., amino acids 36-140 of SEQ ID NO:6        (SEQ ID NO:15) or amino acids 9-113 of SEQ ID NOs:1, 3 or 4.    -   (xii) the 104AA polypeptide sequence designated herein        alternatively as NBN104 or N-9, which possesses the 104 carboxy        terminal amino acids of a neublastin polypeptide, e.g., amino        acids 37-140 of SEQ ID NO:6 (SEQ ID NO:16) or amino acids 10-113        of SEQ ID NOs:1, 3 or 4.    -   (xiii) the 103AA polypeptide sequence designated herein as        NBN103, which possesses the 103 carboxy terminal amino acids of        a neublastin polypeptide, e.g., amino acids 38-140 of SEQ ID        NO:6 (SEQ ID NO:17) or amino acids 11-113 of SEQ ID NOs:1, 3 or        4.    -   (xiv) the 102AA polypeptide sequence designated herein as        NBN102, which possesses the 102 carboxy terminal amino acids of        a neublastin polypeptide, e.g., amino acids 39-140 of SEQ ID        NO:6 (SEQ ID NO:18) or amino acids 12-113 of SEQ ID NOs:1, 3 or        4.    -   (xv) the 101AA polypeptide sequence designated herein as NBN101,        which possesses the 101 carboxy terminal amino acids of a        neublastin polypeptide, e.g., amino acids 40-140 of SEQ ID NO:6        (SEQ ID NO:19) or amino acids 13-113 of SEQ ID NOs:1, 3 or4.    -   (xvi) the 100AA polypeptide sequence designated herein as        NBN100, which possesses the 100 carboxy terminal amino acids of        a neublastin polypeptide, e.g., amino acids 41-140 of SEQ ID        NO:6 (SEQ ID NO:20) or amino acids 14-113 of SEQ ID NOs:1, 3 or        4.    -   (xvii) the 99AA polypeptide sequence designated herein        alternatively as NBN99 or N-14, which possesses the 99 carboxy        terminal amino acids of a neublastin polypeptide, e.g., amino        acids 42-140 of SEQ ID NO:6 (SEQ ID NO:21) or amino acids 15-113        of SEQ ID NOs:1, 3 or 4.

The polypeptide sequences of these truncated neublastin polypeptides areshown in Table 4 for NBN113 through NBN99. Disulfide bridge formation isas described for Table 3.

A mutated neublastin polypeptide according to the invention can be,e.g., at least 80%, 85%, 90%, 95%, 98% or 99% identical to amino acids8-113 of SEQ ID NO:1. In some embodiments, the amino acid sequence ofthe mutated neublastin polypeptide includes the amino acid sequence of anaturally occurring rat, human or mouse neublastin polypeptide at aminoacids 1-94 and 96-113 of the mutated neublastin polypeptide, e.g., thepolypeptide has the amino acid sequence of SEQ ID NOs: 2, 3, or 4 atthese positions.

A mutated neublastin polypeptide differing in sequence from thosedisclosed in SEQ ID NOs:1-4 may include one or more conservative aminoacid substitutions. Alternatively, or in addition, the mutatedneublastin polypeptide may differ by one or more non conservative aminoacid substitutions, or by deletions or insertions. Preferably, thesubstitutions, insertions or deletions do not abolish the isolatedprotein's biological activity.

A conservative substitution is the substitution of one amino acid foranother with similar characteristics. Conservative substitutions includesubstitutions within the following groups: valine, alanine and glycine;leucine, valine, and isoleucine; aspartic acid and glutamic acid;asparagine and glutamine; serine, cysteine, and threonine; lysine andarginine; and phenylalanine and tyrosine. The non-polar hydrophobicamino acids include alanine, leucine, isoleucine, valine, proline,phenylalanine, tryptophan and methionine. The polar neutral amino acidsinclude glycine, serine, threonine, cysteine, tyrosine, asparagine andglutamine. The positively charged (basic) amino acids include arginine,lysine and histidine. The negatively charged (acidic) amino acidsinclude aspartic acid and glutamic acid. Any substitution of one memberof the above-mentioned polar, basic or acidic groups by another memberof the same group can be deemed a conservative substitution.

Other substitutions can be readily identified by those of ordinary skillin the art. For example, for the amino acid alanine, a substitution canbe taken from any one of D-alanine, glycine, beta-alanine, cysteine andD-cysteine. For lysine, a replacement can be any one of D-lysine,arginine, D-arginine, homo-arginine, methionine, D-methionine,ornithine, or D-ornithine. Generally, substitutions in functionallyimportant regions that may be expected to induce changes in theproperties of isolated polypeptides are those in which: (i) a polarresidue, e.g., serine or threonine, is substituted for (or by) ahydrophobic residue, e.g., leucine, isoleucine, phenylalanine, oralanine; (ii) a cysteine residue is substituted for (or by) any otherresidue; (iii) a residue having an electropositive side chain, e.g.,lysine, arginine or histidine, is substituted for (or by) a residuehaving an electronegative side chain, e.g., glutamic acid or asparticacid; or (iv) a residue having a bulky side chain, e.g., phenylalanine,is substituted for (or by) one not having such a side chain, e.g.,glycine. The likelihood that one of the foregoing non-conservativesubstitutions may alter functional properties of the protein is alsocorrelated to the position of the substitution with respect tofunctionally important regions of the protein. Some non-conservativesubstitutions may accordingly have little or no effect on biologicalproperties.

In many cases, a polymer-conjugated mutated neublastin polypeptide has alonger serum half-life relative to the half-life of the wild-typepolypeptide or mutated polypeptide in the absence of the polymer. Insome embodiments, the polymer conjugated mutated neublastin polypeptidehas significantly increased potency in vivo relative to the potency ofthe polypeptide or glycosylated-polypeptide in the absence of thepolymer.

The polymer-conjugated neublastin polypeptide can be provided as a dimerthat includes at least one polymer-conjugated neublastin polypeptide. Insome embodiments, the dimer is a homodimer of polymer-conjugated mutatedneublastin polypeptides. In other embodiments, the dimer is a homodimerof polymer-conjugated mutated truncated neublastin polypeptides. Inother embodiments, the dimer is a heterodimer that includes onepolymer-conjugated mutated neublastin polypeptide and one wild-typeneublastin polypeptide. In other embodiments, the dimer is a heterodimerthat includes one polymer-conjugated mutated neublastin polypeptide, andone polymer-conjugated wild-type neublastin polypeptide where thepolymer conjugation is at the amino-terminus, and where the polypeptidesmay or may not be truncated. Other dimers include heterodimers orhomodimers of polymer-conjugated mutated neublastin polypeptide formsthat may or may not be truncated.

Provided in the invention are mature and truncated mutated polypeptidesequences comprising the carboxy-terminal-most amino acid residues ofthe preproNBN polypeptide, such as provided in SEQ ID NO:5, and whichare designated herein as NBN#, where # represents the number ofcarboxy-terminal residues remaining in the referenced neublastinpolypeptide. Polymer-conjugated neublastin polypeptides present in thebioactive neublastin dimers may be products of a protease cleavagereaction or a chemical cleavage reaction, or may be expressed fromrecombinant DNA construct, or may be synthesized. Example neublastinpolypeptides include, e.g., NBN140, NBN116, and NBN113. Additionalneublastin polypeptides of the invention include NBN112, NBN111, NBN110,NBN109, NBN108, NBN107, NBN106, NBN105, NBN104, NBN103, NBN102, NBN101,NBN100 and NBN99 (SEQ ID NOS:8-21).

A preferred polymer-conjugated neublastin polypeptide is a homodimer ofNBN106-N95K conjugated either to three 10 kDa PEG moieties (“3×10 kDaPEG NBN106-N95K”) or to four 10 kDa PEG moieties (“4×10 kDa PEGNBN106-N95K”). Also preferred is a mixed population of NBN106-N95Khomodimers conjugated either to three 10 kDa PEG moieties or to four 10kDa PEG moieties, referred to herein as “3(,4)×10 kDa PEG NBN106-N95K”.Also preferred is a 3(,4)×10 kDa PEG NBN106-N95K homodimer, wherein thetwo amino-terminal amino acids are covalently linked to PEG moieties andthe third and/or fourth PEG moiety is covalently linked to one or bothsubstituted N95K residue(s).

In some embodiments, the polymer-conjugated neublastin polypeptide isbased on the consensus sequence of SEQ ID NO:1. In certain embodiments,a polymer-conjugated neublastin polypeptide includes amino acids 1-7 ofSEQ ID NO:1 in addition to amino acids 8-113.

In some embodiments, the polymer-conjugated neublastin polypeptide, whendimerized, binds GFRα3. In some embodiments, the polymer-conjugatedneublastin polypeptide, when dimerized, stimulates tyrosinephosphorylation of a RET polypeptide, either on its own or when bound toGFRα3.

In some embodiments, the polymer-conjugated neublastin polypeptide, whendimerized, enhances neuron survival, e.g., enhances survival of asensory neuron.

In some embodiments, the polymer-conjugated neublastin polypeptide, whendimerized, reduces or reverses pathological changes of a neuron, such asa sensory neuron.

In some embodiments, the polymer-conjugated neublastin polypeptide, whendimerized, enhances survival of a neuron, e.g., an autonomic neuron, ora dopaminergic neuron.

In some embodiments, the polymer-conjugated neublastin polypeptideincludes one, two, three, four or more of the amino acid substitutionsselected from the group consisting of an amino acid other than arginineat position 14 in the amino acid sequence of the polymer-conjugatedpolypeptide, an amino acid other than arginine at position 39 in theamino acid sequence of the polymer-conjugated polypeptide, an amino acidother than arginine at position 68 of the polymer-conjugatedpolypeptide, and an amino acid other than asparagine at position 95 ofthe polymer-conjugated polypeptide. In some embodiments, the amino acidat one or more of the amino acid at positions 14, 39, 68, and 95 islysine. Preferably, amino acids 8-94 and 96-113 of thepolymer-conjugated neublastin polypeptide are at least 90% identical toamino acids 8-94 and 96-113 of SEQ ID NO:1. More preferably, the aminoacids sequences are at least 95% identical thereto. Most preferably, theamino acid sequence of the polymer-conjugated neublastin polypeptideincludes the amino acid sequence of a naturally occurring human, mouseor rat neublastin polypeptide at amino acids 8-94 and 96-113 of thepolymer-conjugated neublastin polypeptide. For example, amino acids 8-94and 96-113 of the polymer-conjugated neublastin polypeptide can includethe amino acid sequence of amino acids 8-94 and 96-113 of SEQ ID NO:1,SEQ ID NO:2, SEQ ID NO:3 or SEQ ID NO: 4. In the above embodiments, thepreferred residue at amino acid position 95 is a lysine or a cysteine.

The invention includes a construct that is a heterodimer or a homodimercontaining polymer-conjugated neublastin fusion proteins, e.g., thepolyhistidine (His)-tagged neublastin provided in SEQ ID NO:36, or aneublastin fusion protein where the fusion moiety is an immunoglobulin(Ig) polypeptide,serum albumin polypeptide or a replicase-derivedpolypeptide. Neublastin fusion proteins can have enhancedpharmacokinetic and bioavailability properties in vivo.

The invention provides a nucleic acid molecule encoding a mature ortruncated neublastin polypeptide, with a mutated polypeptide sequence.The nucleic acid molecule encoding a provided neublastin polypeptide ispreferably provided in a vector, e.g., an expression vector. A mutatedneublastin nucleic acid molecule, or a vector including the same, can beprovided in a cell. The cell can be, e.g., a mammalian cell, fungalcell, yeast cell, insect cell, or bacterial cell. A preferred mammaliancell is a Chinese hamster ovary cell (“CHO cell”).

Also provided by the invention is a method of making apolymer-conjugated neublastin polypeptide, by culturing a cellcontaining a nucleic acid encoding a neublastin polypeptide underconditions allowing for expression of a neublastin polypeptide. In someembodiments, the neublastin is conjugated to a naturally occurringmoiety. In specific embodiments, the naturally occurring moiety is aglycosyl moiety. In certain embodiments, the glycosylated neublastin isexpressed, e.g., in a CHO cell. The invention further includes aneublastin polypeptide expressed in a cell. Similar nucleic acids,vectors, host cells, and polypeptide production methods are disclosedherein for the fusion proteins (such as the neublastin-serum albuminfusion proteins) of this invention.

In some embodiments, a neublastin polypeptide that is expressed in acell is recovered and conjugated to a polymer. In some embodiments, thepolymer is a polyalkylene glycol moiety. In particular embodiments, thepolymer is a PEG moiety.

Specifically provided by the invention is a composition that includes amutated neublastin polypeptide coupled to a non-naturally occurringpolymer. The mutated neublastin polypeptide in the compositionpreferably includes an amino acid sequence at least 70% identical toamino acids 8-113 of SEQ ID NO:1, provided that the polymer-conjugatedneublastin polypeptide includes one or more of the amino acidsubstitutions selected from the group consisting of an amino acid otherthan arginine at position 14 in the amino acid sequence of thepolymer-conjugated polypeptide, an amino acid other than arginine atposition 39 in the amino acid sequence of the polymer-conjugatedpolypeptide, an amino acid other than arginine at position 68 of thepolymer-conjugated polypeptide, and an amino acid other than asparagineat position 95 of the polymer-conjugated polypeptide, wherein thepositions of the amino acids are numbered in accordance with thepolypeptide sequence of SEQ ID NO:1.

The invention includes a stable, aqueous soluble conjugated neublastinpolypeptide or mutated neublastin polypeptide complex comprising aneublastin polypeptide or mutated neublastin polypeptide coupled to aPEG moiety, wherein the neublastin polypeptide or mutated neublastinpolypeptide is coupled to the PEG moiety by a labile bond. In someembodiments, the labile bond is cleavable by biochemical hydrolysis,proteolysis, or sulfhydryl cleavage. In some embodiments, the labilebond is cleavable under in vivo conditions.

Also provided by the invention is a method for making a modifiedneublastin polypeptide that has prolonged serum half-life relative to awild-type neublastin. The method included providing a neublastinpolypeptide or mutated neublastin polypeptide, and coupling thepolypeptide or mutatedneublastin polypeptide to a non-naturallyoccurring polymer moiety, thereby forming a coupled polymer neublastinpolypeptide composition.

The polymer-conjugated mutated neublastin polypeptides of this inventioninclude one or more amino acid substitutions in which, for example, anamino acid other than arginine occurs at position 14 in the amino acidsequence of the polymer-conjugated polypeptide, an amino acid other thanarginine at position 39 occurs in the amino acid sequence of thepolymer-conjugated polypeptide, an amino acid other than arginine atposition 68 occurs in the polymer-conjugated polypeptide, or an aminoacid other than asparagine at position 95 occurs in thepolymer-conjugated polypeptide, when the positions of the amino acidsare numbered in accordance with the polypeptide sequence of SEQ ID NO:1.

Synthesis and Isolation of Wild-Type and Mutated Neublastin Polypeptides

Neublastin polypeptides can be isolated using methods known in the art.Naturally occurring neublastin polypeptides can be isolated from cellsor tissue sources by an appropriate purification scheme using standardprotein purification techniques. Alternatively, mutated neublastinpolypeptides can be synthesized chemically using standard peptidesynthesis techniques. The synthesis of short amino acid sequences iswell established in the peptide art. See, e.g., Stewart, et al., SolidPhase Peptide Synthesis (2d ed., 1984).

In some embodiments, mutated neublastin polypeptides are produced byrecombinant DNA techniques. For example, a nucleic acid moleculeencoding a mutated neublastin polypeptide can be inserted into a vector,e.g., an expression vector, and the nucleic acid can be introduced intoa cell. Suitable cells include, e.g., mammalian cells (such as humancells or CHO cells), fungal cells, yeast cells, insect cells, andbacterial cells. When expressed in a recombinant cell, the cell ispreferably cultured under conditions allowing for expression of amutated neublastin polypeptide. The mutated neublastin polypeptide canbe recovered from a cell suspension if desired. As used herein,“recovered” means that the mutated polypeptide is removed from thosecomponents of a cell or culture medium in which it is present prior tothe recovery process. The recovery process may include one or morerefolding or purification steps.

Mutated neublastin polypeptides can be constructed using any of severalmethods known in the art. One such method is site-directed mutagenesis,in which a specific nucleotide (or, if desired a small number ofspecific nucleotides) is changed in order to change a single amino acid(or, if desired, a small number of predetermined amino acid residues) inthe encoded neublastin polypeptide. Those skilled in the art recognizethat site-directed mutagenesis is a routine and widely used technique.In fact, many site-directed mutagenesis kits are commercially available.One such kit is the “Transformer Site Directed Mutagenesis Kit” sold byClontech Laboratories (Palo Alto, Calif.).

Practice of the present invention will employ, unless indicatedotherwise, conventional techniques of cell biology, cell culture,molecular biology, microbiology, recombinant DNA, protein chemistry, andimmunology, which are within the skill of the art. Such techniques aredescribed in the literature. See, for example, Molecular Cloning: ALaboratory Manual, 2nd edition. (Sambrook, Fritsch and Maniatis, eds.),Cold Spring Harbor Laboratory Press, 1989; DNA Cloning, Volumes I and II(D. N. Glover, ed), 1985; Oligonucleotide Synthesis, (M. J. Gait, ed.),1984; U.S. Pat. No. 4,683,195 (Mullis et al.,); Nucleic AcidHybridization (B. D. Haines and S. J. Higgins, eds.), 1984;Transcription and Translation (B. D. Hames and S. J. Higgins, eds.),1984; Culture of Animal Cells (R. I. Freshney, ed). Alan R. Liss, Inc.,1987; Immobilized Cells and Enzymes, IRL Press, 1986; A Practical Guideto Molecular Cloning (13.Perbal), 1984; Methods in Enzymology, Volumes154 and 155 (Wu et al., eds), Academic Press, New York; Gene TransferVectors for Mammalian Cells (J. H. Miller and M. P. Calos, eds.), 1987,Cold Spring Harbor Laboratory; Immunochernical Methods in Cell andMolecular Biology (Mayer and Walker, eds.), Academic Press, London,1987; Handbook of Experiment Immunology, Volumes I-IV (D. M. Weir and C.C. Blackwell, eds.), 1986; Manipulating the Mouse Embryo, Cold SpringHarbor Laboratory Press, 1986.

Polymer Conjugation of Neublastin Polypeptides

Chemically modified neublastin polypeptides may be prepared by one ofskill in the art based upon the present disclosure. The chemicalmoieties preferred for conjugation to a neublastin polypeptide arewater-soluble polymers. A water-soluble polymer is advantageous becausethe protein to which it is attached does not precipitate in an aqueousenvironment, such as a physiological environment. Preferably, thepolymer will be pharmaceutically acceptable for the preparation of atherapeutic product or composition.

If desired, a single polymer molecule may be employed for conjugationwith a neublastin polypeptide, although more than one polymer moleculecan be attached as well. Conjugated neublastin compositions of theinvention may find utility in both in vivo as well as non-in vivoapplications. Additionally, it will be recognized that the conjugatingpolymer may utilize any other groups, moieties, or other conjugatedspecies, as appropriate to the end use application. By way of example,it may be useful in some applications to covalently bond to the polymera functional moiety imparting UV-degradation resistance, orantioxidation, or other properties or characteristics to the polymer. Asa further example, it may be advantageous in some applications tofunctionalize the polymer to render it reactive or cross-linkable incharacter, to enhance various properties or characteristics of theoverall conjugated material. Accordingly, the polymer may contain anyfunctionality, repeating groups, linkages, or other constituentstructures that do not preclude the efficacy of the conjugatedneublastin composition for its intended purpose.

One skilled in the art will be able to select the desired polymer basedon such considerations as whether the polymer/protein conjugate will beused therapeutically, and if so, the desired dosage, circulation time,resistance to proteolysis, and other considerations. The effectivenessof the derivatization may be ascertained by administering thederivative, in the desired form (e.g., by osmotic pump, or, morepreferably, by injection or infusion, or, further formulated for oral,pulmonary or other delivery routes), and determining its effectiveness.

Suitable water-soluble polymers include, but are not limited to, PEG,copolymers of ethylene glycol/propylene glycol, carboxymethylcellulose,dextran, polyvinyl alcohol, polyvinyl pyrrolidone, poly-1, 3-dioxolane,poly-1, 3, 6-trioxane, ethylene/maleic anhydride copolymer,polyaminoacids (either homopolymers or random copolymers), and dextranor poly(n-vinyl pyrrolidone) PEG, propropylene glycol homopolymers,polypropylene oxide/ethylene oxide co-polymers, polyoxyethylated polyols(e.g., glycerol), polyvinyl alcohol, and mixtures thereof.

The polymer may be of any suitable molecular weight, and may be branchedor unbranched.

For PEG, suitable average molecular weight is between about 2 kDa andabout 100 kDa. This provides for ease in handling and manufacturing.Those of skill in the art will appreciate that in preparations of PEG,some molecules will weigh more, some less, than the stated molecularweight. Thus, molecular weight is typically specified as “averagemolecular weight.” Other molecular weights (sizes) may be used,depending on the desired therapeutic profile (e.g., the duration ofsustained release desired; the effects, if any, on biological activity;the ease in handling; the degree or lack of antigenicity and other knowneffects of PEG on a therapeutic protein). In various embodiments, themolecular weight is about 2 kDa, about 5 kDa, about 10 kDa, about 15kDa, about 20 kDa, about 25 kDa, about 30 kDa, about 40 kDa or about 100kDa. In certain preferred embodiments, the average molecular weight ofeach PEG chain is about 20 kDa. In certain preferred embodiments, theaverage molecular weight is about 10 kDa.

The number of polymer molecules so attached may vary, and one skilled inthe art will be able to ascertain the effect on function. One maymono-derivatize, or may provide for a di-, tri-, tetra- or somecombination of derivatization, with the same or different chemicalmoieties (e.g., polymers, such as different weights of PEGs). Theproportion of polymer molecules to protein (or polypeptide) moleculeswill vary, as will their concentrations in the reaction mixture. Ingeneral, the optimum ratio (in terms of efficiency of reaction in thatthere is no excess unreacted protein or polymer) will be determined byfactors such as the desired degree of derivatization (e.g., mono, di-,tri-, etc.), the molecular weight of the polymer selected, whether thepolymer is branched or unbranched, and the reaction conditions.

The PEG molecules (or other chemical moieties) should be attached to theprotein with consideration of effects on functional or antigenic domainsof the protein. There are a number of attachment methods available tothose skilled in the art. See, e.g., EP 0 401384 (coupling PEG toG-CSF); Malik et al., Exp. Hematol. 20: 1028-1035, 1992 (reportingPEGylation of GM-CSF using tresyl chloride).

For example, PEG may be covalently bound (PEGylation) through amino acidresidues via a reactive group, such as, a free amino or carboxyl group.The amino acid residues having a free amino group include lysineresidues and the amino-terminal amino acid residue. Those having a freecarboxyl group include aspartic acid residues, glutamic acid residues,and the C-terminal amino acid residue. Sulfhydryl groups may also beused as a reactive group for attaching the PEG molecule(s). Fortherapeutic purposes, attachment can be at an amino group, e.g. at theN-terminus or lysine group. One may specifically desire anamino-terminal chemically modified protein.

Using PEG as an illustration of the present compositions, one may selectfrom a variety of PEG molecules (by molecular weight, branching, etc.),the proportion of PEG molecules to protein (or peptide) molecules in thereaction mix, the type of PEGylation reaction to be performed, and themethod of obtaining the selected amino-terminally PEGylated protein. Themethod of obtaining the amino-terminal PEGylated preparation (i.e.,separating this moiety from other monoPEGylated moieties if necessary)may be by purification of the amino-terminal PEGylated material from apopulation of PEGylated protein molecules. Selective amino-terminalchemical modification may be accomplished by reductive alkylation thatexploits differential reactivity of different types of primary aminogroups (lysine versus the amino-terminal) available for derivatizationin a particular protein. Under the appropriate reaction conditions,substantially selective derivatization of the protein at theamino-terminus with a carbonyl group containing polymer is achieved. Forexample, one may selectively PEGylate the amino-terminus of the proteinby performing the reaction at a pH which allows one to take advantage ofthe pKa differences between the epsilon (ε)-amino group of the lysineresidues and that of the alpha (α)-amino group of the amino-terminalresidue of the protein. By such selective derivatization, attachment ofa water soluble polymer to a protein is controlled: the conjugation withthe polymer takes place predominantly at the amino-terminus of theprotein and no significant modification of other reactive groups, suchas the lysine side chain amino groups, occurs.

Using reductive alkylation, the water-soluble polymer may be of the typedescribed above, and should have a single reactive aldehyde for couplingto the protein. PEG propionaldehyde, containing a single reactivealdehyde, may be used.

The present invention includes mutated neublastin polypeptides that areexpressed in prokaryotes or eukaryotes or made synthetically. In someembodiments, the neublastin is glycosylated. In some specificembodiments, the neublastin dimer is polymer-conjugated at eachamino-terminus and glycosylated at each internal Asn95 residue. In otherembodiments, the mutated neublastin dimer is polymer-conjugated at eachamino-terminus and polymer-conjugated at one or both internal Lys95residues.

PEGylation may be carried out by any suitable PEGylation reaction.Various PEGylation chemistries are known in the art. See, e.g., Focus onGrowth Factors, 3 (2): 4-10, 1992; EP 0 154 316; EP 0 401 384; and theother publications cited herein that relate to PEGylation. ThePEGylation may be carried out via an acylation reaction or an alkylationreaction with a reactive PEG molecule (or an analogous reactivewater-soluble polymer).

PEGylation by acylation generally involves reacting an active esterderivative of PEG. Any known or subsequently discovered reactive PEGmolecule may be used to carry out the PEGylation. A preferred activatedPEG ester is PEG esterified to N-hydroxysuccinimide (NHS). As usedherein, “acylation” includes without limitation the following types oflinkages between the therapeutic protein and a water soluble polymersuch as PEG: amide, carbamate, urethane, and the like. See, BioconjugateChem. 5: 133-140, 1994. Reaction conditions may be selected from any ofthose known in the PEGylation art or those subsequently developed, butshould avoid conditions such as temperature, solvent, and pH that wouldinactivate the neublastin protein or polypeptide to be modified.

PEGylation by acylation will generally result in a poly-PEGylatedneublastin protein product. Preferably, the connecting linkage will bean amide. Also preferably, the resulting product will be substantiallyonly (e.g., >95%) mono, di- or tri-PEGylated. However, some species withhigher degrees of PEGylation may be formed in amounts depending on thespecific reaction conditions used. If desired, more purified PEGylatedspecies may be separated from the mixture, particularly unreactedspecies, by standard purification techniques, including, among others,dialysis, salting-out, ultrafiltration, ion-exchange chromatography, gelfiltration chromatography and electrophoresis.

PEGylation by alkylation generally involves reacting a terminal aldehydederivative of PEG with neublastin in the presence of a reducing agent.PEGylation by alkylation can also result in poly-PEGylated neublastinprotein products. In addition, one can manipulate the reactionconditions to favor PEGylation substantially only at the α-amino groupof the amino-terminus of neublastin (i.e., a mono-PEGylated protein). Ineither case of mono-PEGylation or poly-PEGylation, the PEG groups arepreferably attached to the protein via a —CH₂—NH— group. With particularreference to the —CH₂— group, this type of linkage is referred to hereinas an “alkyl” linkage.

Derivatization via reductive alkylation to produce a mono-PEGylatedproduct exploits differential reactivity of different types of primaryamino groups (lysine versus the amino-terminal) available forderivatization. The reaction is performed at a pH that allows one totake advantage of the pKa differences between the ε-amino groups of thelysine residues and that of the α-amino group of the amino-terminalresidue of the protein. By such selective derivatization, attachment ofa water soluble polymer that contains a reactive group such as analdehyde, to a protein is controlled: the conjugation with the polymertakes place predominantly at the amino-terminus of the protein and nosignificant modification of other reactive groups, such as the lysineside chain amino groups, occurs.

The polymer molecules used in both the acylation and alkylationapproaches may be selected from among water-soluble polymers asdescribed above. The polymer selected should be modified to have asingle reactive group, such as an active ester for acylation or analdehyde for alkylation, preferably, so that the degree ofpolymerization may be controlled as provided for in the present methods.An exemplary reactive PEG aldehyde is PEG propionaldehyde, which iswater stable, or mono C1-C10 alkoxy or aryloxy derivatives thereof (see,U.S. Pat. No. 5,252,714). The polymer may be branched or unbranched. Forthe acylation reactions, the polymer(s) selected should have a singlereactive ester group. For the present reductive alkylation, thepolymer(s) selected should have a single reactive aldehyde group.Generally, the water-soluble polymer will not be selected fromnaturally-occurring glycosyl residues since these are usually made moreconveniently by mammalian recombinant expression systems. The polymermay be of any molecular weight, and may be branched or unbranched.

An exemplary water-soluble polymer for use herein is PEG. As usedherein, polyethylene glycol encompasses any of the forms of PEG thathave been used to derivatize other proteins, including but not limitedto, e.g., mono-(C1-C10) alkoxy- or aryloxy-PEG.

In general, chemical derivatization may be performed under any suitablecondition used to react a biologically active substance with anactivated polymer molecule. Methods for preparing a PEGylated neublastinwill generally comprise the steps of (a) reacting a neublastin proteinor polypeptide with PEG (such as a reactive ester or aldehyde derivativeof PEG) under conditions whereby the molecule becomes attached to one ormore PEG groups, and (b) obtaining the reaction product(s). In general,the optimal reaction conditions for the acylation reactions will bedetermined case by case based on known parameters and the desiredresult. For example, the larger the ratio of PEG:protein, the greaterthe percentage of poly-PEGylated product.

Reductive alkylation to produce a substantially homogeneous populationof mono-polymer/neublastin will generally comprise the steps of: (a)reacting a neublastin protein or polypeptide with a reactive PEGmolecule under reductive alkylation conditions, at a pH suitable topen-nit selective modification of the α-amino group at the aminoterminus of neublastin; and (b) obtaining the reaction product(s).

For a substantially homogeneous population of mono-polymer/neublastin,the reductive alkylation reaction conditions are those that permit theselective attachment of the water-soluble polymer moiety to theamino-terminus of neublastin. Such reaction conditions generally providefor pKa differences between the lysine amino groups and the α-aminogroup at the amino-terminus (the pKa being the pH at which 50% of theamino groups are protonated and 50% are not). The pH also affects theratio of polymer to protein to be used. In general, if the pH is lower,a larger excess of polymer to protein will be desired (i.e., the lessreactive the amino-terminal α-amino group, the more polymer needed toachieve optimal conditions). If the pH is higher, the polymer:proteinratio need not be as large (i.e., more reactive groups are available, sofewer polymer molecules are needed). For purposes of the presentinvention, the pH will generally fall within the range of 3-9,preferably 3-6.

Another important consideration is the molecular weight of the polymer.In general, the higher the molecular weight of the polymer, the fewerpolymer molecules may be attached to the protein. Similarly, branchingof the polymer should be taken into account when optimizing theseparameters. Generally, the higher the molecular weight (or the morebranches) the higher the polymer:protein ratio. In general, for thePEGylation reactions included herein, the preferred average molecularweight is about 2 kDa to about 100 kDa. The preferred average molecularweight is about 5 kDa to about 50 kDa, particularly preferably about 10kDa to about 20 kDa. The preferred total molecular weight is about 10kDa to about 40 kDa.

In some embodiments, the neublastin polypeptide is linked to the polymervia a terminal reactive group on the polypeptide. Alternatively, or inaddition, the neublastin polypeptide may be linked via the side chainamino group of an internal lysine residue, e.g., a lysine residueintroduced into the amino acid sequence of a naturally occurringneublastin polypeptide. Thus, conjugations can also be branched from thenon terminal reactive groups. The polymer with the reactive group(s) isdesignated herein as “activated polymer”. The reactive group selectivelyreacts with reactive groups on the protein, e.g., free amino.

Attachment may occur in the activated polymer at any availableneublastin amino group such as the alpha amino groups or the epsilonamino groups of a lysine residue or residues introduced into the aminoacid sequence of a neublastin polypeptide. Free carboxylic groups,suitably activated carbonyl groups, hydroxyl, guanidyl, imidazole,oxidized carbohydrate moieties and mercapto groups of the neublastin (ifavailable) can also be used as attachment sites.

Generally from about 1.0 to about 10 moles of activated polymer per moleof protein, depending on protein concentration, is employed. The finalamount is a balance between maximizing the extent of the reaction whileminimizing non-specific modifications of the product and, at the sametime, defining chemistries that will maintain optimum activity, while atthe same time optimizing, if possible, the half-life of the protein.Preferably, at least about 50% of the biological activity of the proteinis retained, and most preferably near 100% is retained.

The polymer can be coupled to the neublastin polypeptide using methodsknown in the art. For example, in one embodiment, the polyalkyleneglycol moiety is coupled to a lysine group of the mutated neublastinpolypeptide. Linkage to the lysine group can be performed with anN-hydroxylsuccinimide (NHS) active ester such as PEG succinimidylsuccinate (SS-PEG) and succinimidyl propionate (SPA-PEG). Suitablepolyalkylene glycol moieties include, e.g., carboxymethyl-NHS,norleucine-NHS, SC-PEG, tresylate, aldehyde, epoxide, carbonylimidazole,and PNP carbonate.

Additional amine reactive PEG linkers can be substituted for thesuccinimidyl moiety. These include, e.g. isothiocyanates,nitrophenylcarbonates, epoxides, and benzotriazole carbonates.Conditions are preferably chosen to maximize the selectivity and extentor reaction.

If desired, polymer-conjugated neublastin polypeptides may contain atag, e.g., a tag that can subsequently be released by proteolysis. Thus,the lysine moiety can be selectively modified by first reacting aHis-tag modified with a low molecular weight linker such as Traut'sreagent (Pierce) which will react with both the lysine andamino-terminus, and then releasing the his tag. The polypeptide willthen contain a free SH group that can be selectively modified with a PEGcontaining a thiol reactive head group such as a maleimide group, avinylsulfone group, a haloacetate group, or a free or protected SH.

Traut's reagent can be replaced with any linker that will set up aspecific site for PEG attachment. By way of example, Traut's reagentcould be replaced with SPDP, SMPT, SATA, or SATP (all available fromPierce). Similarly one could react the protein with an amine reactivelinker that inserts a maleimide (for example SMCC, AMAS, BMPS, MBS,EMCS, SMPB, SMPH, KMUS, or GMBS), a haloacetate group (SBAP, SIA, SIAB),or a vinylsulfone group and react the resulting product with a PEG thatcontains a free SH. The only limitation to the size of the linker thatis employed is that it cannot block the subsequent removal of theamino-terminal tag.

Thus, in other embodiments, the polyalkylene glycol moiety is coupled toa cysteine group of the mutated neublastin polypeptide. Coupling can beeffected using, e.g., a maleimide group, a vinylsulfone group, ahaloacetate group, and a thiol group.

In preferred embodiments, the polymer-conjugated neublastin polypeptidein the composition has a longer serum half-life relative to thehalf-life of the neublastin polypeptide in the absence of the polymer.Alternatively, or in addition, the polymer-conjugated neublastinpolypeptide dimer in the composition binds GFRα, activates RET,normalizes pathological changes of a neuron, enhances survival of aneuron, or ameliorates neuropathic pain, or performs a combination ofthese physiological functions. Assays for determining whether apolypeptide enhances survival of a neuron, or normalizes pathologicalchanges of a neuron, are described in, e.g., WO00/01815. Preferably, theneuron is a sensory neuron, an autonomic neuron, or a dopaminergicneuron.

In preferred embodiments, the composition is provided as a stable,aqueous soluble conjugated neublastin polypeptide complex comprising aneublastin polypeptide or mutated neublastin polypeptide coupled to aPEG moiety. If desired, the neublastin polypeptide or mutated neublastinpolypeptide may be coupled to the PEG moiety by a labile bond. Thelabile bond can be cleaved in, e.g., biochemical hydrolysis,proteolysis, or sulfhydryl cleavage. For example, the bond can becleaved under in vivo (physiological) conditions.

Other reaction parameters, such as solvent, reaction times,temperatures, etc., and means of purification of products, can bedetermined case by case based on the published information relating toderivatization of proteins with water soluble polymers.

If desired, a single polymer molecule for conjugation per neublastinpolypeptides may be employed. Alternatively, more than one polymermolecule may be attached. Conjugated neublastin compositions of theinvention may find utility in both in vivo as well as non-in vivoapplications. Additionally, it will be recognized that the conjugatingpolymer may utilize any other groups, moieties, or other conjugatedspecies, as appropriate to the end use application. By way of example,it may be useful in some applications to covalently bond to the polymera functional moiety imparting UV-degradation resistance, orantioxidation, or other properties or characteristics to the polymer. Asa further example, it may be advantageous in some applications tofunctionalize the polymer to render it reactive or cross-linkable incharacter, to enhance various properties or characteristics of theoverall conjugated material. Accordingly, the polymer may contain anyfunctionality, repeating groups, linkages, or other constituentstructures that do not preclude the efficacy of the conjugatedneublastin mutein composition for its intended purpose.

Illustrative polymers that may usefully be employed to achieve thesedesirable characteristics are described herein below in exemplaryreaction schemes. In covalently bonded peptide applications, the polymermay be functionalized and then coupled to free amino acid(s) of thepeptide(s) to form labile bonds.

The reactions may take place by any suitable method used for reactingbiologically active materials with inert polymers, preferably at aboutpH 5-8, e.g., pH 5, 6, 7, or 8, if the reactive groups are on the alphaamino group at the amino-terminus. Generally the process involvespreparing an activated polymer and thereafter reacting the protein withthe activated polymer to produce the soluble protein suitable forformulation. The above modification reaction can be performed by severalmethods, which may involve one or more steps.

Linear and branched forms of PEG can be used as well as other alkylforms. The length of the PEG can be varied. Most common forms vary insize from 2K-100 kDa. While the present examples report that targetedPEGylation at the amino-terminus does not affect pharmokineticproperties, the fact that the material retained physiological functionindicates that modification at the site or sites disclosed herein is notdeleterious. Consequently, in generating mutant forms of neublastin thatcould provide additional sites of attachment through insertion of lysineresidues, the likely outcome that these forms would be PEGylated both atthe lysine and at the amino-terminus is encompassed by the invention.

One or more sites on a neublastin polypeptide can be coupled to apolymer. For example, one two, three, four, or five PEG moieties can beattached to the polypeptide. In some embodiments, a PEG moiety isattached at the amino terminus and/or amino acids 14, 39, 68, and 95 ofa neublastin polypeptide numbered as shown in Table 1 and SEQ ID NO:1.

In advantageous embodiments, the polymer-conjugated neublastinpolypeptide in the composition has a longer serum half-life relative tothe half-life of the neublastin wild-type or mutated polypeptide in theabsence of the polymer. Alternatively, or in addition, thepolymer-conjugated neublastin polypeptide in the composition bindsGFRα3, activates RET, normalizes pathological changes of a neuron,enhances survival of a neuron, or ameliorates neuropathic pain, orperforms a combination of these physiological functions.

In some embodiments, the mutated neublastin polypeptide or polymerconjugate in the complex has a physiological activity selected from thegroup consisting of: GFRα3 binding, RET activation, normalization ofpathological changes of a neuron, enhancing neuron survival, orameliorating neuropathic pain.

Also provided by the invention are multimeric polypeptides that includea polymer-conjugated neublastin polypeptide. The multimeric polypeptidesare preferably provided as purified multimeric polypeptides. Examples ofmultimeric complexes include, e.g., dimeric complexes. The multimericcomplex can be provided as a heteromeric or homomeric complex. Thus, themultimeric complex can be a heterodimeric polymer-conjugated polypeptidecomplex including one mutated neublastin polypeptide and one non-mutatedneublastin or a heterodimeric polymer-conjugated polypeptide complexincluding two or more mutated neublastin polypeptides.

In some embodiments, the polymer-conjugated neublastin polypeptide bindsGFRα3. Preferably, binding of the polymer-conjugated neublastinpolypeptide stimulates phosphorylation of a RET polypeptide. Todetermine whether a polypeptide binds GFRα3, assays can be performed asdescribed in WO00/01815. For example, the presence of neublastin in themedia of CHO cell line supernatants can be described using a modifiedform of a ternary complex assay described by Sanicola et al. (Proc.Natl. Acad. Sci. USA, 1997, 94: 6238). In this assay, the ability ofGDNF-like molecules can be evaluated for their ability to mediatebinding between the extracellular domain of RET and the variousco-receptors, GFRα1, GFRα2, and GFRα3. Soluble forms of RET and theco-receptors are generated as fusion proteins. A fusion protein betweenthe extracellular domain of rat RET and placental alkaline phosphatase(RET-AP) and a fusion protein between the extracellular domain of ratGFRα-1 (disclosed in published application WO9744356; Nov. 27, 1997) andthe Fc domain of human IgG1 (rGFR(α1-Ig) have been described (Sanicolaet al., Proc. Natl. Acad. Sci. USA 1997, 94: 6238).

The polymer of the invention is preferably a polyalkylene glycol moiety,and more preferably a PEG moiety. In some embodiments, a polymericmoiety has an average molecular weight of about 100 Da to about 25,000Da; of about 1000 Da to about 20,000 Da; or of about 5000 Da to about20,000 Da. In some embodiments, at least one polymeric moiety has anaverage molecular weight of about 5000 Da; an average molecular weightof about 10,000 Da; or an average molecular weight of about 20,000 Da.

The functional group on the polyalkylene glycol moiety can be, e.g.,carboxymethyl-NHS, norleucine-NHS, SC-PEG, tresylate, aldehyde, epoxide,carbonylimidazole, or PNP carbonate. Coupling can occur via anN-hydroxylsuccinimide (NHS) active ester. The active ester can be, e.g.,PEG succinimidyl succinate (SS-PEG), succinimidyl butyrate (SPB-PEG), orsuccinimidyl propionate (SPA-PEG). In some embodiments, the polyalkyleneglycol moiety is coupled to a cysteine group of the neublastinpolypeptide or mutated neublastin polypeptide. For example, coupling canoccur via a maleimide group, a vinylsulfone group, a haloacetate group,and a thiol group. In various embodiments, the neublastin polypeptide ormutated neublastin polypeptide comprises one, two, three, or four PEGmoieties.

In some embodiments, the polymer is coupled to the polypeptide at a siteon the neublastin that is an N terminus. In some embodiments, thepolymer is coupled to the polypeptide at a site in a non-terminal aminoacid of the neublastin polypeptide or mutated neublastin polypeptide. Insome embodiments, the polymer is coupled to a solvent exposed amino acidof the neublastin polypeptide or mutated neublastin polypeptide.

In some embodiments, the polymer is coupled to the neublastinpolypeptide or mutated neublastin polypeptide at a residue selected fromthe group consisting of the amino terminal amino acid of thepolymer-conjugated polypeptide, position 14 in the amino acid sequenceof the neublastin polypeptide or mutated neublastin polypeptide,position 39 in the amino acid sequence of the neublastin polypeptide ormutated neublastin polypeptide, position 68 in the amino acid sequenceof the neublastin polypeptide or mutated neublastin polypeptide, andposition 95 in the amino acid sequence of the neublastin polypeptide ormutated polypeptide.

Polymer-Conjugated Neublastin Fusion Proteins

If desired, the polymer-conjugated neublastin polypeptide can beprovided as a fusion protein. Fusion polypeptide derivatives of proteinsof the invention also include various structural forms of the primaryprotein that retain biological activity.

Polymer-conjugated neublastin-serum albumin fusions can be constructedusing methods known in the art. Any of a number of cross-linkers thatcontain a corresponding amino reactive group and thiol reactive groupcan be used to link neublastin to serum albumin. Examples of suitablelinkers include amine reactive cross-linkers that insert a thiolreactive-maleimide. These include, e.g., SMCC, AMAS, BMPS, MBS, EMCS,SMPB, SMPH, KMUS, or GMBS. Other suitable linkers insert a thiolreactive-haloacetate group. These include, e.g., SBAP, SIA, SIAB andthat provide a protected or non protected thiol for reaction withsulfhydryl groups to product a reducible linkage are SPDP, SMPT, SATA,or SATP all of which are commercially available (e.g., PierceChemicals). One skilled in the art can similarly envision withalternative strategies that will link the amino-terminus of neublastinwith serum albumin.

It is also envisioned that one skilled in the art can generateconjugates to serum albumin that are not targeted at the amino-terminusof neublastin or at the thiol moiety on serum albumin. If desired,neublastin-serum albumin fusions can be generated using geneticengineering techniques, wherein neublastin is fused to the serum albumingene at its amino-terminus carboxy-terminus, or at both ends.

Any neublastin conjugate that results in a product with a prolongedhalf-life, for example, in vivo or, specifically, in animals (includinghumans) can be generated using a similar strategy. Another example of aneublastin conjugate that results in a product with a prolongedhalf-life in vivo is a neublastin fusion protein where the fusionpartner is an Ig.

Other derivatives of polymer-conjugated neublastins include covalent oraggregate conjugates of mutated neublastin or its fragments with otherproteins or polypeptides, such as by synthesis in recombinant culture asadditional amino-termini, or carboxy-termini. For example, theconjugated peptide may be a signal (or leader) polypeptide sequence atthe amino-terminal region of the protein which co-translationally orpost-translationally directs transfer of the protein from its site ofsynthesis to its site of function inside or outside of the cell membraneor wall (e.g., the yeast alpha-factor leader). Neublastin receptorproteins can comprise peptides added to facilitate purification oridentification of neublastin (e.g., histidine/neublastin fusions). Theamino acid sequence of neublastin can also be linked to the peptideAsp-Tyr-Lys-Asp-Asp-Asp-Asp-Lys (DYKDDDDK) (SEQ ID NO:22) (Hopp et al.,Biotechnology 6:1204 (1988)). The latter sequence is highly antigenicand provides an epitope reversibly bound by a specific monoclonalantibody, enabling rapid assay and facile purification of expressedrecombinant protein.

This sequence is also specifically cleaved by bovine mucosalenterokinase at the residue immediately following the Asp-Lys pairing.

Bioactive Polypeptides

The polypeptides of the invention may be provided in any bioactive form,including the form of pre-pro-proteins, pro-proteins, mature proteins,glycosylated proteins, non-glycosylated proteins, phosphorylatedproteins, non-phosphorylated proteins, truncated forms, or any otherposttranslational modified protein. A bioactive neublastin polypeptideincludes a polypeptide that, for example, when dimerized, alone or inthe presence of a cofactor (such as GFRα3, or RET), binds to RET,induces dimerization of RET, and autophosphorylation of RET.

The polypeptides of the invention may in particular be an N-glycosylatedpolypeptide, which polypeptide preferably is glycosylated at theN-residues indicated in the sequence listings.

In some embodiments, a polypeptide of the invention has the amino acidsequence presented as SEQ ID NO:6, holding a glycosylated asparagineresidue at position 122; or the amino acid sequence presented as SEQ IDNO:14, holding a glycosylated asparagine residue at position 95, or theanalogous position in any mutated neublastin polypeptide when alignedby, e.g., ClustalW computer software.

In some embodiments, the polypeptide of the invention has the amino acidsequence presented as SEQ ID NO:23, referred to herein as NBN113-N95K,containing a lysine residue substituted for the asparagine residue atposition 95 of SEQ ID NO:2; or the amino acid sequence presented as SEQID NO:24, referred to herein as NBN106-N95K; or the analogous positionin any mutated neublastin polypeptide when aligned by, e.g., ClustalWcomputer software.

This invention also includes mutated neublastin fusion proteins, such asIg-fusions, as described, e.g., in U.S. Pat. No. 5,434,131, or serumalbumin fusions.

In some embodiments, the invention provides a polypeptide having theamino acid sequence shown as SEQ ID NO:1 with the exception of onesubstitution, or an amino acid sequence that has at least about 85%,preferably at least about 90%, more preferably at least about 95%, morepreferably at least about 98%, and most preferably at least about 99%identity to the sequence presented as SEQ ID NO:1.

In other embodiments, the invention provides a polypeptide having theamino acid sequence of SEQ ID NO:2 with the exception of onesubstitution, or an amino acid sequence that has at least about 85%,preferably at least about 90%, more preferably at least about 95%, morepreferably at least about 98%, and most preferably at least about 99%identity to the sequence presented as SEQ ID NO:2.

In some embodiments, the invention provides a polypeptide having theamino acid sequence of SEQ ID NO:3 with the exception of onesubstitution, or an amino acid sequence that has at least about 85%,preferably at least about 90%, more preferably at least about 95%, morepreferably at least about 98%, and most preferably at least about 99%identity to the sequence presented as SEQ ID NO:3.

In some embodiments, the invention provides a polypeptides having theamino acid sequence of SEQ ID NO:4 with the exception of onesubstitution, or an amino acid sequence that has at least about 85%,preferably at least about 90%, more preferably at least about 95%, morepreferably at least about 98%, and most preferably at least about 99%identity to the sequence presented as SEQ ID NO:4.

In some embodiments, the invention provides a polypeptide having theamino acid sequence of SEQ ID NO:5 with the exception of onesubstitution, or an amino acid sequence that has at least about 85%,preferably at least about 90%, more preferably at least about 95%, morepreferably at least about 98%, and most preferably at least about 99%identity to the sequence presented as SEQ ID NO:5.

In some embodiments, the invention provides a polypeptides having theamino acid sequence of SEQ ID NO:6 with the exception of onesubstitution, or an amino acid sequence that has at least about 85%,preferably at least about 90%, more preferably at least about 95%, morepreferably at least about 98%, and most preferably at least about 99%identity to the sequence presented as SEQ ID NO:6.

In some embodiments, the invention provides a polypeptide having theamino acid sequence of SEQ ID NO:7 with the exception of onesubstitution, or an amino acid sequence that has at least about 85%,preferably at least about 90%, more preferably at least about 95%, morepreferably at least about 98%, and most preferably at least about 99%identity to the sequence presented as SEQ ID NO:7.

In some embodiments, the invention provides a polypeptide having theamino acid sequence of any one of SEQ ID NOs:8-21 with the exception ofone substitution, or an amino acid sequence that has at least about 85%,preferably at least about 90%, more preferably at least about 95%, morepreferably at least about 98%, and most preferably at least about 99%identity to the sequence presented as any one of SEQ ID NOs:8-21.

In some embodiments, the invention provides a polypeptide having theamino acid sequence of SEQ ID NO:36 with the exception of onesubstitution, or an amino acid sequence that has at least about 85%,preferably at least about 90%, more preferably at least about 95%, morepreferably at least about 98%, and most preferably at least about 99%identity to the sequence presented as SEQ ID NO:36.

In further embodiments, the invention provides a polypeptide having theamino acid sequence of any one of SEQ ID NOS:1-21 and 36 with theexception of one substitution, or an amino acid sequence that has atleast about 85%, preferably at least about 90%, more preferably at leastabout 95%, more preferably at least about 98%, and most preferably atleast about 99% identity to any one of the sequences presented as SEQ IDNOS:1-21 and 36.

In other embodiments, the mutated polypeptide of the invention holds theGDNF subfanily fingerprint, i.e. the conserved cysteine amino acidresidues designated in Tables 3 and 4.

In some embodiments, the invention provides a mutated polypeptideencoded by a polynucleotide sequence capable of hybridizing under highstringency conditions with the polynucleotide sequence encoding thepolypeptide of SEQ ID NO:1, its complementary strand, or a sub-sequencethereof. In some embodiments, the mutated polypeptide of the inventionis encoded by a polynucleotide sequence having at least 70% identity tothe polynucleotide sequence encoding the polypeptide of SEQ ID NO:1.

In some embodiments, the invention provides novel polypeptides encodedby a polynucleotide sequence capable of hybridizing under highstringency conditions with the polynucleotide sequence encoding thepolypeptide of SEQ ID NO:2, its complementary strand, or a sub-sequencethereof. In some embodiments, the mutated polypeptide of the inventionis encoded by a polynucleotide sequence having at least 70% identity tothe polynucleotide sequence encoding the polypeptide of SEQ ID NO:2.

In some embodiments, the invention provides mutated polypeptides encodedby a polynucleotide sequence capable of hybridizing under highstringency conditions with the polynucleotide sequence encoding thepolypeptide of any one of SEQ ID NOs:8-21, its complementary strand, ora sub-sequence thereof. In other embodiments, the mutated polypeptide ofthe invention is encoded by a polynucleotide sequence having at least70% identity to the polynucleotide sequence encoding the polypeptide ofany one of SEQ ID NO: 8-21.

In some embodiments, the invention provides novel polypeptides encodedby a polynucleotide sequence capable of hybridizing under highstringency conditions with the polynucleotide sequence encoding thepolypeptide of SEQ ID NO:36, its complementary strand, or a sub-sequencethereof. In some embodiments, the mutated polypeptide of the inventionis encoded by a polynucleotide sequence having at least 70% identity tothe polynucleotide sequence encoding the polypeptide of SEQ ID NO:36.

Biological Origin

A non-conjugated neublastin polypeptide dimer can be isolated and thenconjugated to one or more polymers to obtain a polymer conjugatedneublastin polypeptide dimer of the invention. The neublastinpolypeptide dimer can be isolated from a mammalian cell, preferably froma human cell or from a cell of murine origin or from a cell of Chinesehamster ovary origin.

Neurotrophic Activity

Modified neublastin polypeptides, including truncated neublastinpolypeptides, of the invention are useful for moderating metabolism,growth, differentiation, or survival of a nerve or neuronal cell. Inparticular, modified neublastin polypeptides are used to treat oralleviate a disorder or disease of a living animal, e.g., a human, whichdisorder or disease is responsive to the activity of a neurotrophicagent. Such treatments and methods are described in more detail below.

Pharmaceutical Compositions Comprising Neublastin-Polymer Conjugates

Also provided is a pharmaceutical composition comprising a modifiedneublastin polypeptide dimer of the present invention.

The polymer-neublastin conjugates of the invention may be administeredper se as well as in the form of pharmaceutically acceptable esters,salts, and other physiologically functional derivatives thereof. In suchpharmaceutical and medicament formulations, the polymer-conjugatedneublastin conjugate preferably is utilized together with one or morepharmaceutically acceptable carrier(s) and optionally any othertherapeutic ingredients.

The carrier(s) must be pharmaceutically acceptable in the sense of beingcompatible with the other ingredients of the formulation and not undulydeleterious to the recipient thereof. The polymer-conjugated neublastinis provided in an amount effective to achieve a desired pharmacologicaleffect or medically beneficial effect, as described herein, and in aquantity appropriate to achieve the desired bioavailable in vivo dose orconcentration.

The formulations include those suitable for parenteral as well as nonparenteral administration, and specific administration modalitiesinclude oral, rectal, buccal, topical, nasal, ophthalmic, subcutaneous,intramuscular, intravenous, transdermal, intrathecal, intra-articular,intra-arterial, sub-arachnoid, bronchial, lymphatic, vaginal, andintra-uterine administration. Formulations suitable for aerosol andparenteral administration, both locally and systemically, are preferred.

When the polymer-conjugated neublastin is utilized in a formulationcomprising a liquid solution, the formulation advantageously may beadministered orally, bronchially, or parenterally. When thepolymer-conjugated neublastin is employed in a liquid suspensionformulation or as a powder in a biocompatible carrier formulation, theformulation may be advantageously administered orally, rectally, orbronchially. Alternatively, it may be administered nasally orbronchially, via nebulization of the powder in a carrier gas, to form agaseous dispersion of the powder that is inspired by the patient from abreathing circuit comprising a suitable nebulizer device.

The formulations comprising the proteins of the present invention mayconveniently be presented in unit dosage forms and may be prepared byany of the methods well known in the art of pharmacy. Such methodsgenerally include the step of bringing the active ingredient(s) intoassociation with a carrier that constitutes one or more accessoryingredients.

Typically, the formulations are prepared by uniformly and intimatelybringing the active ingredient(s) into association with a liquidcarrier, a finely divided solid carrier, or both, and then, ifnecessary, shaping the product into dosage forms of the desiredformulation.

Formulations of the present invention suitable for oral administrationmay be presented as discrete units such as capsules, cachets, tablets,or lozenges, each comprising a predetermined amount of the activeingredient as a powder or granules; or a suspension in an aqueous liquoror a non-aqueous liquid, such as a syrup, an elixir, an emulsion, or adraught.

Formulations suitable for parenteral administration convenientlycomprise a sterile aqueous preparation of the active conjugate, whichpreferably is isotonic with the blood of the recipient (e.g.,physiological saline solution). Such formulations may include suspendingagents and thickening agents or other microparticulate systems which aredesigned to target the compound to blood components or one or moreorgans. The formulations may be presented in unit-dose or multi-doseform.

Nasal spray formulations comprise purified aqueous solutions of theactive conjugate with preservative agents and isotonic agents. Suchformulations are preferably adjusted to a pH and isotonic statecompatible with the nasal mucus membranes.

Formulations for rectal administration may be presented as a suppositorywith a suitable carrier such as cocoa butter, hydrogenated fats, orhydrogenated fatty carboxylic acid. Ophthalmic formulations such as eyedrops are prepared by a similar method to the nasal spray, except thatthe pH and isotonic factors are preferably adjusted to match that of theeye.

Topical formulations comprise the conjugates of the invention dissolvedor suspended in one or more media, such as mineral oil, petroleum,polyhydroxy alcohols, or other bases used for topical pharmaceuticalformulations.

In addition to the aforementioned ingredients, the formulations of thisinvention may further include one or more accessory ingredient(s)selected from diluents, buffers, flavoring agents, disintegrants,surface active agents, thickeners, lubricants, preservatives (includingantioxidants), and the like. The foregoing considerations apply also tothe neublastin fusion proteins of the invention (e.g., neublastin-humanserum albumin fusion proteins).

Accordingly, the present invention includes the provision of suitablefusion proteins for in vitro stabilization of a polymer-conjugatedneublastin conjugate in solution, as a preferred illustrativeapplication of the invention. The fusion proteins may be employed forexample to increase the resistance to enzymatic degradation of thepolymer-conjugated neublastin polypeptide and provides a means ofimproving shelf life, room temperature stability, and the like. It isunderstood that the foregoing considerations apply also to theneublastin-serum albumin fusion proteins (including the humanneublastin-human serum albumin fusion proteins) of the invention.

Methods of Treatment

The compositions of the invention may be used for treating oralleviating a disorder or disease in a mammal, e.g., a primate includinga human, which disorder or disease is responsive to the activity ofneurotrophic agents.

The compositions of the invention may be used directly via, e.g.,injected, implanted or ingested pharmaceutical compositions to treat apathological process responsive to the neublastin polypeptides. Thecompositions may be used for alleviating a disorder or disease of aliving animal body, including a human, which disorder or disease isresponsive to the activity of neurotrophic agents. The disorder ordisease may in particular be damage of the nervous system caused bytrauma, surgery, ischemia, infection, metabolic diseases, nutritionaldeficiency, malignancy or toxic agents, and genetic or idiopathicprocesses.

The damage may in particular have occurred to sensory neurons or retinalganglion cells, including neurons in the dorsal root ganglia or in anyof the following tissues: the geniculate, petrosal and nodose ganglia;the vestibuloacoustic complex of the eighth cranial nerve; theventrolateral pole of the maxillomandibular lobe of the trigeminalganglion; and the mesencephalic trigeminal nucleus.

In some embodiments of the method of the invention, the disease ordisorder is a neurodegenerative disease involving lesioned and traumaticneurons, such as traumatic lesions of peripheral nerves, the medulla,and/or the spinal cord, cerebral ischemic neuronal damage, neuropathyand especially peripheral neuropathy, peripheral nerve trauma or injury,ischemic stroke, acute brain injury, acute spinal cord injury, nervoussystem tumors, multiple sclerosis, exposure to neurotoxins, metabolicdiseases such as diabetes or renal dysfunctions and damage caused byinfectious agents, neurodegenerative disorders including Alzheimer'sdisease, Huntington's disease, Parkinson's disease, Parkinson-Plussyndromes, progressive Supranuclear Palsy (Steele-Richardson-OlszewskiSyndrome), Olivopontocerebellar Atrophy (OPCA), Shy-Drager Syndrome(multiple systems atrophy), Guamanian parkinsonism dementia complex,amyotrophic lateral sclerosis, or any other congenital orneurodegenerative disease, and memory impairment connected to dementia.

In some embodiments, sensory and/or autonomic system neurons can betreated. In particular, nociceptive and mechanoreceptive neurons can betreated, more particularly A-delta fiber, C-fiber and A-beta fiberneurons. In addition, sympathetic and parasympathetic neurons of theautonomic system can be treated.

In some embodiments, motor neuron diseases such as amyotrophic lateralsclerosis (“ALS”) and spinal muscular atrophy can be treated. In otherembodiments, the neublastin molecules of this invention to can be usedto enhance nerve recovery following traumatic injury. Alternatively, orin addition, a nerve guidance channel with a matrix containingpolymer-conjugated neublastin polypeptides, or fusion or conjugates ofmutated neublastin polypeptides can be used in the herein describedmethods. Such nerve guidance channels are disclosed, e.g., U.S. Pat. No.5,834,029.

In some embodiments, the compositions disclosed herein (andpharmaceutical compositions comprising same) are used in the treatmentof peripheral neuropathies. Among the peripheral neuropathies includedfor treatment with the molecules of this invention are trauma-inducedneuropathies, e.g., those caused by physical injury or disease state,physical damage to the brain, physical damage to the spinal cord, strokeassociated with brain damage, and neurological disorders related toneurodegeneration. Also included herein are those neuropathies secondaryto infection, toxin exposure, and drug exposure. Still further includedherein are those neuropathies secondary to systemic or metabolicdisease. For example, the herein disclosed compositions can also be usedto treat chemotherapy-induced neuropathies (such as those caused bydelivery of chemotherapeutic agents, e.g., taxol or cisplatin); toxininduced neuropathies, drug-induced neuropathies,vitamin-deficiency-induced neuropathies; idiopathic neuropathies;diabetic neuropathies; and post-herpetic neuralgias. See, e.g., U.S.Pat. Nos. 5,496,804 and 5,916,555.

Additional conditions that can be treated according to the invention aremono-neuropathies, mono-multiplex neuropathies, and poly-neuropathies,including axonal and demyelinating neuropathies.

In some embodiments, the compositions of the invention (andpharmaceutical compositions comprising same) are used in the treatmentof various disorders in the eye, including photoreceptor loss in theretina in patients afflicted with macular degeneration, retinitispigmentosa, glaucoma, and similar diseases.

Methods and Pharmaceutical Compositions

This invention provides methods for treating neuropathic pain, fortreating tactile allodynia, and for reducing loss of pain sensitivityassociated with neuropathy. The present methods use polymer conjugatedneublastin polypeptide dimers, including dimers comprising bioactivefull-length neublastin polypeptides or bioactive truncated neublastinpolypeptides. In addition, the invention provides pharmaceuticalcompositions comprising a polymer conjugated neublastin polypeptidedimer suspended, dissolved, or dispersed in a pharmaceuticallyacceptable carrier.

1. Treatment of Neuropathic Pain

In one embodiment, the invention includes a method for treatingneuropathic pain in a subject comprising administering to the subject aneffective amount of a polymer conjugated neublastin polypeptide dimer.In some embodiments, the invention includes a method for treatingneuropathic pain in a subject comprising administering to the subject apharmaceutically effective amount of a polymer conjugated neublastinpolypeptide dimer comprising, for example, wild-type, truncated ormutated neublastin polypeptides, including, e.g., any one of SEQ IDNOS:1, 2, 6-21 and 36 or a mutated form thereof, either alone, or byalso administering to the subject an effective amount of ananalgesia-inducing compound selected from the group consisting ofopioids, anti-arrhythmics, topical analgesics, local anaesthetics,anticonvulsants, antidepressants, corticosteroids and non-steroidalanti-inflammatory drugs (NSAIDS). In a preferred embodiment, theanalgesia-inducing compound is an anticonvulsant. In another preferredembodiment, the analgesia-inducing compound is gabapentin((1-aminomethyl)cyclohexane acetic acid) or pregabalin(S-(+)-4-amino-3-(2-methylpropyl)butanoic acid).

The neublastin polypeptides and nucleic acids of this invention (andpharmaceutical compositions comprising polymer conjugated neublastinpolypeptide dimers described herein) are used in the treatment of painassociated with peripheral neuropathies. Among the peripheralneuropathies which can be treated according to this invention aretrauma-induced neuropathies, e.g., those caused by physical injury ordisease state, physical damage to the brain, physical damage to thespinal cord, stroke associated with brain damage, and neurologicaldisorders related to neurodegeneration.

The invention also provides treatments of chemotherapy-inducedneuropathies (such as those caused by delivery of chemotherapeuticagents, e.g., taxol or cisplatin); toxin-induced neuropathies,drug-induced neuropathies, pathogen-induced (e.g., virus induced)neuropathies, vitamin-deficiency-induced neuropathies; idiopathicneuropathies; and diabetic neuropathies. See, e.g., U.S. Pat. Nos.5,496,804 and 5,916,555, each herein incorporated by reference. Theinvention still further can be used for treatment of mono-neuropathies,mono-multiplex neuropathies, and poly-neuropathies, including axonal anddemyelinating neuropathies, using the neublastin nucleotides andpolypeptides of this invention.

The neuropathic pain may be associated with a number of peripheralneuropathies, including: (a) trauma-induced neuropathics, (b)chemotherapy-induced neuropathies, (c) toxin-induced neuropathies(including but not limited to neuropathies induced by alcoholism,vitamin B6 intoxication, hexacarbon intoxication, amiodarone,chloramphenicol, disulfiram, isoniazide, gold, lithium, metronidazole,misonidazole, nitrofurantoin), (d) drug-induced neuropathies, includingtherapeutic drug-induced neuropathic pain (such as caused by anti-canceragents, particularly anti-cancer agents selected from the groupconsisting of taxol, taxotere, cisplatin, nocodazole, vincristine,vindesine and vinblastine; and such as caused by anti-viral agents,particularly anti-viral agents selected from the group consisting ofddI, DDC, d4T, foscarnet, dapsone, metronidazole, and isoniazid), (e)vitamin-deficiency-induced neuropathies (including but not limited tovitamin B12 deficiency, vitamin B6 deficiency, and vitamin Edeficiency), (f) idiopathic neuropathies, (g) diabetic neuropathies, (h)pathogen-induced nerve damage, (i) inflammation-induced nerve damage,(j) neurodegeneration, (k) hereditary neuropathy (including but notlimited to Friedreich ataxia, familial amyloid polyneuropathy, Tangierdisease, Fabry disease), (l) metabolic disorders (including but notlimited to renal insufficiency and hypothyroidism), (m) infectious andviral neuropathies (including but not limited to neuropathic painassociated with leprosy, Lyme disease, neuropathic pain associated withinfection by a virus, particularly a virus selected from the groupconsisting of a herpes virus (e.g. herpes zoster which may lead topost-herpetic neuralgia), a human immunodeficiency virus (HIV), and apapilloma virus), (n) auto-immune neuropathies (including but notlimited to Guillain-Barre syndrome, chronic inflammatory de-myelinatingpolyneuropathy, monoclonal gammopathy of undetermined significance andpolyneuropathy), (o) trigeminal neuralgia and entrapment syndromes(including but not limited to Carpel tunnel), and (p) other neuropathicpain syndromes including post-traumatic neuralgia, phantom limb pain,multiple sclerosis pain, complex regional pain syndromes (including butnot limited to reflex sympathetic dystrophy, causalgia),neoplasia-associated pain, vasculitic/angiopathic neuropathy, andsciatica. Neuropathic pain may be manifested as allodynia, hyperalgesia,spontaneous pain or phantom pain.

2. Treatment of Tactile Allodynia

The term “tactile allodynia” typically refers to the condition in asubject where pain is evoked by stimulation of the skin (e.g. touch)that is normally innocuous. This invention includes a method fortreating tactile allodynia in a subject.

In some embodiments, tactile allodynia is treated by administering tothe subject a pharmaceutically effective amount of a polymer conjugatedmutated neublastin polypeptide dimer alone.

In a related embodiment, the invention includes a method for treatingtactile allodynia in a subject, either by administering to the subjectan effective amount of a polymer conjugated neublastin polypeptide dimercontaining truncated wild-type or mutated neublastin polypeptides,including, e.g., at least one of SEQ ID NOS:1, 2, 6-21 and 36 or amutated form thereof, either alone, or by administering to the subjectan effective amount of a neublastin polypeptide with an effective amountof an analgesia-inducing compound selected from the group consisting ofopioids, anti-arrhythmics, topical analgesics, local anaesthetics,anticonvulsants, antidepressants, corticosteroids and NSAIDS. In apreferred embodiment, the analgesia-inducing compound is ananticonvulsant. In another preferred embodiment, the analgesia-inducingcompound is gabapentin ((1-aminomethyl)cyclohexane acetic acid) orpregabalin (S-(+)-4-amino-3-(2-methylpropyl)butanoic acid).

In some embodiments, a polymer conjugated mutated neublastin polypeptidedimer is administered in association with a therapeutic agent, includingbut not limited to an anti-cancer agent or an anti-viral agent.Anti-cancer agents include, but are not limited to, taxol, taxotere,cisplatin, nocodazole, vincristine, vindesine and vinblastine.Anti-viral agents include, but are not limited to, ddI, DDC, d4T,foscarnet, dapsone, metronidazole, and isoniazid.

3. Treatment for Reduction of Loss of Pain Sensitivity

In another embodiment, the invention includes a method for reducing theloss of pain sensitivity in a subject afflicted with a neuropathy. In apreferred embodiment, the neuropathy is diabetic neuropathy. In apreferred embodiment, the loss of pain sensitivity is a loss in thermalpain sensitivity. This invention contemplates both prophylactic andtherapeutic treatment.

In prophylactic treatment, a polymer conjugated mutated neublastinpolypeptide dimer is administered to a subject at risk of developingloss of pain sensitivity; such subjects would be expected to be subjectswith an early stage neuropathy. The treatment with neublastin under suchcircumstances would serve to treat at-risk patients preventively.

In therapeutic treatment, a polymer conjugated mutated neublastinpolypeptide dimer is administered to a subject who has experienced lossof pain sensitivity as a result of affliction with a neuropathy; suchsubjects would be expected to be subjects with a late stage neuropathy.The treatment with a polymer conjugated mutated neublastin polypeptidedimer under such circumstances would serve to rescue appropriate painsensitivity in the subject.

4. Treatment of Viral Infections and Viral-Associated Neuropathies

Prophylactic treatment of infectious and viral neuropathies iscontemplated. Prophylactic treatment is indicated after determination ofviral infection and before onset of neuropathic pain. During treatment,a polymer conjugated mutated neublastin polypeptide dimer isadministered to prevent appearance of neuropathic pain including but notlimited to neuropathic pain associated with leprosy, Lyme disease,neuropathic pain associated with infection by a virus, particularly avirus selected from the group consisting of a herpes virus (and moreparticularly by a herpes zoster virus, which may lead to post-herpeticneuralgia), a human immunodeficiency virus (HIV), and a papillomavirus). In an alternative embodiment, a polymer conjugated mutatedneublastin polypeptide dimer is administered to reduce the severity ofneuropathic pain, should it appear.

Symptoms of acute viral infection often include the appearance of arash. Other symptoms include, for example, the development of persistentpain in the affected area of the body, which is a common complication ofa herpes zoster infection (shingles). Post-herpetic neuralgia can lastfor a month or more, and may appear several months after any rash-likesymptoms have disappeared.

5. Treatment of Painful Diabetic Neuropathy

Prophylactic treatment of painful diabetic neuropathy is contemplated.Prophylactic treatment of diabetic neuropathies would commence afterdetermination of the initial diagnosis of diabetes ordiabetes-associated symptoms and before onset of neuropathic pain.Prophylactic treatment of painful diabetic neuropathy may also commenceupon determining that a subject is at risk for developing diabetes ordiabetes-associated symptoms. During treatment, a polymer conjugatedmutated neublastin polypeptide dimer is administered to preventappearance of neuropathic pain. In an alternative embodiment, a polymerconjugated mutated neublastin polypeptide dimer is administered toreduce the severity of neuropathic pain that has already appeared.

6. Nervous System Disorders

In a further aspect, the invention provides a method of treating orpreventing a nervous system disorder in a subject (such as a human), byadministering to a subject in need thereof a therapeutically effectiveamount of a polymer-conjugated neublastin polypeptide, a compositioncontaining a neublastin polypeptide or mutated neublastin polypeptidecoupled to a polymer, or a complex that includes a stable, aqueoussoluble conjugated neublastin polypeptide or mutated neublastinpolypeptide complex comprising a neublastin polypeptide or mutatedneublastin polypeptide coupled to a polyalkylene moiety such as, e.g.,PEG.

The nervous system disorder can be a peripheral nervous system disorder,such as a peripheral neuropathy or a neuropathic pain syndrome. Humansare preferred subjects for treatment.

A polymer-conjugated neublastin polypeptide dimer of the invention isuseful for treating a defect in a neuron, including without limitationlesioned neurons and traumatized neurons. Peripheral nerves thatexperience trauma include, but are not limited to, nerves of the medullaor of the spinal cord. Inventive polymer-conjugated neublastinpolypeptide dimers are useful in the treatment of neurodegenerativedisease, e.g., cerebral ischemic neuronal damage; neuropathy, e.g.,peripheral neuropathy, Alzheimer's disease, Huntington's disease,Parkinson's disease, amyotrophic lateral sclerosis (ALS). Suchneublastin polypeptide dimers can be used in the treatment of impairedmemory, e.g., memory impairment associated with dementia.

Additional examples of conditions or diseases are disorders of theperipheral nervous system, the medulla, or the spinal cord, as well astrauma-induced neuropathies, chemotherapy-induced neuropathies,toxin-induced neuropathies, drug-induced neuropathies,vitamin-deficiency-induced neuropathies; idiopathic neuropathies; anddiabetic neuropathies, neuropathic pain associated with toxin-inducednerve damage, pathogen-induced nerve damage, inflammation-induced nervedamage, or neurodegeneration. An inventive neublastin polypeptide dimeris additionally useful for treating neuropathic pain, for treatingtactile allodynia and for reducing loss of pain sensitivity associatedwith neuropathy.

7. Dosage

The foregoing methods contemplate administering a to the subject,preferably systemically, a formulation comprising a polymer conjugatedmutated neublastin polypeptide dimer that may or may not be truncated ata dosage from 0.01 μg/kg to 1000 μg/kg body weight of the subject, perdose. Preferably the dosage is from 1 μg/kg to 100 μg/kg body weight ofthe subject, per dose. More preferably the dosage is from 1 μg/kg to 30μg/kg body weight of the subject, per dose, e.g., from 3 μg/kg to 10μg/kg body weight of the subject, per dose. Therapeutically effectiveamounts of the formulation of the invention may be administered to asubject in need thereof in a dosage regimen ascertainable by one ofskill in the art, without undue experimentation.

8. Delivery

The polypeptide dimer used in the foregoing methods can be administeredvia any suitable delivery system, and preferably from the groupconsisting of intravenous delivery, intramuscular delivery,intrapulmonary delivery, subcutaneous delivery, and intraperitonealdelivery, most preferably via intramuscular delivery, intravenousdelivery, or subcutaneous delivery. The neublastin polypeptide used inthe foregoing methods can also be administered via intrathecal delivery.

Administration of a polymer-conjugated neublastin polypeptide dimer canbe, e.g., systemic or local. The formulations include those suitable forparenteral as well as non parenteral administration, and specificadministration modalities include oral, rectal, buccal, topical, nasal,ophthalmic, subcutaneous, intramuscular, intravenous, transdermal,intrathecal, intra-articular, intra-arterial, sub-arachnoid, bronchial,lymphatic, vaginal, and intra-uterine administration. Formulationssuitable for aerosol and parenteral administration, both locally andsystemically, are included. Preferred formulations are suitable forsubcutaneous, intramuscular, or intravenous administration.

8. Regimes

In some embodiments, the frequency of dosing for the polypeptide dimerof the invention provides for administering to the subject a formulationthree times a week for two weeks. In order to optimize therapeuticefficacy, a polymer conjugated mutated neublastin polypeptide dimer isfirst administered at different dosing regimens. The unit dose andregimen depend on factors that include, e.g., the species of mammalimmunized, its immune status, the body weight of the mammal. Typically,protein levels in tissue are monitored using appropriate screeningassays as part of a clinical testing procedure, e.g., to determine theefficacy of a given treatment regimen.

The frequency of dosing for a polymer conjugated mutated neublastinpolypeptide dimer of this invention is within the skills and clinicaljudgement of physicians. Typically, the administration regime isestablished by clinical trials which may establish optimaladministration parameters. However, the practitioner may vary suchadministration regimes according to the subject's age, health, weight,sex and medical status. The frequency of dosing may also vary betweenacute and chronic treatments for neuropathy. In addition, the frequencyof dosing may be varied depending on whether the treatment isprophylactic or therapeutic.

The invention is further illustrated in the following non-limitingexamples.

EXAMPLES Example 1 Bioavailability of Amino-Terminal PEGylatedNeublastin

CHO cell—and E. coli—derived recombinant neublastins were observed to berapidly cleared from circulation if administered intravenously in rats.The proteins were below the threshold of detection in the serumfollowing subcutaneous administration. To increase bioavailability ofneublastin, PEGylated forms of mutated neublastin were constructed.

Because no lysines occur in the neublastin sequence, amine-specificPEGylation chemistries will result in PEGylation of a wild-typeneublastin polypeptide at its amino terminus. Thus, for each neublastindimer, two PEG moieties should be attached. Accordingly, PEG forms werefirst directly targeted to the amino-terminus through amine specificchemistries. Surprisingly, PEGylation of E. coli expressed wild-typeneublastin, even with two 20 kDa PEGs attached, had little benefit onhalf life, indicating that a mechanism based clearance pathway wasoverriding the enhancement in half life that was expected to be achievedby PEGylation.

Example 2 Construction of a PEGylated Mutated Neublastin (N95K)

The bioavailability of mutated neublastin forms PEGylated at internalamino acid residues was next examined. A series of four mutantsreplacing naturally occurring residues at positions 14, 39, 68, and 95,when numbered as shown in SEQ ID NO:1, were designed to insert lysinesat selected sites in the sequence. These lysines would providealternative sites for PEG attachment. These sites were selected usingthe crystal structure of GDNF (Nat. Struct. Biol. 4: 435-8, 1997) as aframework to identify surface residues. The persephin/neublastin chimeramutagenesis study (J. Biol. Chem. 275: 3412-20, 2000) was used toidentify functionally important regions of the structure that should beavoided.

In order to express the wild-type neublastin gene in E. coli, syngeneswere constructed with lower GC content and preferred E. coli codons. Thesyngene was cloned into two vectors, pET19b and pMJB164, a derivative ofpET19b. In pET19b, the sequence encoding the mature domain of neublastin(NBN113) is directly fused to an initiating methionine. In pMJB164, themature domain of neublastin is fused to a histidine tag (i.e. 10histidines) and separated from the histidine tag by an enterokinasecleavage site (SEQ ID NOs: 35 and 36). The initiating methionineprecedes the histidine tag.

TABLE 5 His-tagged Wild-Type Neublastin Nucleotide and PolypeptideSequence His-tagged NBN 1 ATG GGC CAT CAT CAT CAT CAT CAT CAT CAT CATCAC TCG AGC GGC 45 (SEQ ID NO: 35) 1 M   G   H   H   H   H   H   H   H   H   H   H   S   S   G 15 (SEQ IDNO: 36) 46 CAT ATC GAC GAC GAC GAC AAG GCT GGA GGA CCG GGA TCT CGT GCT90 16  H   I   D   D   D   D   K   A   G   G   P   G   S   R   A 30 91CGT GCA GCA GGA GCA CGT GGC TGT CGT CTG CGT TCT CAA CTA GTG 135 31 R   A   A   G   A   R   G   C   R   L   R   S   Q   L   V 45 136 CCGGTG CGT GCA CTC GGA CTG GGA CAC CGT TCC GAC GAA CTA GTA 180 46 P   V   R   A   L   G   L   G   H   R   S   D   E   L   V 60 181 CGTTTT CGT TTT TGT TCA GGA TCT TGT CGT CGT GCA CGT TCT CCG 225 61 R   F   R   F   C   S   G   S   C   R   R   A   R   S   P 75 226 CATGAT CTA TCT CTA GCA TCT CTA CTA GGA GCC GGA GCA CTA AGA 270 76 H   D   L   S   L   A   S   L   L   G   A   G   A   L   R 90 271 CCGCCG CCG GGA TCT AGA CCT GTA TCT CAA CCT TGT TGT AGA CCT 315 91 P   P   P   G   S   R   P   V   S   Q   P   C   C   R   P 105 316 ACTAGA TAC GAA GCA GTA TCT TTC ATG GAC GTA AAC TCT ACA TGG 360 106 T   R   Y   E   A   V   S   F   M   D   V   N   S   T   W 120 361 AGAACC GTA GAT AGA CTA TCT GCA ACC GCA TGT GGC TGT CTA GGA 405 121 R   T   V   D   R   L   S   A   T   A   C   G   C   L   G 135 406 TGATAA TAG   414 136  *   *   *

Two of the mutations (R39 and R68) were targeted at a region that, basedon the distribution of positive charges on the surface, might representa heparin binding site. This site likely contributes to the rapidclearance of the protein. A third site was targeted at N95, the naturalglycosylation site in wild-type neublastin. This site is naturallymodified with a complex carbohydrate structure. Therefore, modificationwith PEG at this site was not expected to impact function. The fourthsite (R14) was selected in a region that was not covered by any other ofthe modifications. A mutant in which the asparagine residue at position95 was replaced with a lysine (the “N95K mutant”) was chosen for thestudies disclosed herein.

Four different mutated rat neublastins comprising one or morealterations in the wild-type sequence of rat neublastin polypeptide wereconstructed. These mutated neublastins contained single amino acidsubstitutions: R14K; R68K; R39K; or N95K. Table 1A identifies theseexemplary point mutations in bold. In the “X₁N₁X₂” nomenclature, X₁refers to an amino acid of a wild-type neublastin polypeptide, N₁ refersto the numerical position of the X₁ amino acids in the sequence, asnumbered according to SEQ ID NO:1, and X₂ refers to an amino acidsubstituted for the wild-type amino acid at the indicated numericalposition N₁.

To construct the rat N95K neublastin mutation, site-directed mutagenesiswas performed on pCMB020, a plasmid encoding wild-type rat neublastin.The wild-type rat neublastin nucleic and the amino acid sequence of thepolypeptide encoded thereby are presented below:

TABLE 6 Wild-type Rat NBN Sequences 1 ATGGAACTGG GACTTGGAGA GCCTACTGCATTGTCCCACT GCCTCCGGCC (SEQ ID NO: 25) 51 TAGGTGGCAA CCAGCCTTGTGGCCAACCCT AGCTGCTCTA GCCCTGCTGA 101 GCAGCGTCAC AGAAGCTTCC CTGGACCCAATGTCCCGCAG CCCCGCCTCT 151 CGCGATGTTC CCTCCCCGGT CCTGGCGCCC CCAACAGACTACCTACCTCG 201 GGGACACACC GCACATCTGT GCAGCGAAAG ACCCCTGCGA CCACCGCCGC251 AGTCTCCTCA GCCCGCACCC CCACCACCGG GTCCCGCGCT CCAGTCTCCT 301CCCGCTGCGC TCCGCGGGGC ACGCGCGGCG CGTGCAGGAA CCCGGAGCAG 351 CCGCCCACGGGCTACAGATG CGCGCGGCTG CCGCCTGCGC TCACAGCTGG 401 TGCCGGTGAG CGCTCTCGGCCTGGCCCACA GCTCCGACGA GCTGATACGT 451 TTCCGCTTCT GCAGCCGTTC GTGCCGCCGAGCACCCTCCC CGCACGATCT 501 CAGCCTGGCC AGCCTGCTGC GCGCCGGGGC CCTGCGGTCTCCTCCCGGGT 551 CCCGGCCGAT CAGCCAGCCC TGTTGCCGGC CCACTCGCTA TGAGGCAGTC601 TCCTTCATGG ACGTGAACAG CACCTGGAGA ACCGTGGACC ATCTCTCCGC 651CACCGCCTGC GGCTGTCTGG GCTGA 1 MELGLGEPTA LSHCLRPRWQ PALWPTLAALALLSSVTEAS LDPMSRSPAS (SEQ ID NO: 26) 51 RDVPSPVLAP PTDYLPGGHTAHLCSERALR PPPQSPQPAP PPPGPALQSP 101 PAALRGARAA RAGTRSSRAR ATDARGCRLRSQLVPVSALG LGHSSDELIR 151 FRFCSGSCRR ARSPHDLSLA SLLGAGALRS PPGSRPISQPCCRPTRYEAV 201 SFMDVNSTWR TVDHLSATAC GCLG*

Mutagenesis of pCM020 using oligonucleotides KD3-210 and KD3-211resulted in formation of the plasmid pCMB027:

(SEQ ID NO: 27) KD3-210 5′-GTATCTTTCATGGACGTTATGTTCTACATGGAGAACC-3′ (SEQID NO: 28) KD3-211 5′-GGTTCTCCATGTAGAACATACGTCCATGAAAGATAC-3′

In pCMB027, the codon encoding asparagine at position 95 was replacedwith a codon encoding lysine.

A R14K mutated neublastin was formed by replacement of a codon encodingarginine at position 14 with a codon encoding lysine in the neublastincoding sequence of pCMB020. Site-directed mutagenesis was performed onpCMB020 using oligonucleotides KD3-254 and KD3-255:

(SEQ ID NO: 29) KD3-254 5′-GCTCGTGCAACGGATGCAAAAGGCTGTCGTCTGCG-3′ (SEQID NO: 30) KD3-255 5′-CGCAGACGACAGCCTTTTGCATCCGTTGCACGAGC-3′

The resulting construct was named pCMB029.

An R68K mutated neublastin was formed by replacement of a codon encodingarginine at position 68 with a codon encoding lysine in the neublastincoding sequence of pCMB020. Site-directed mutagenesis was performed onpCMB020 using oligonucleotides KD3-258 and KD3-259:

(SEQ ID NO: 31) KD3-258 5′-GGAGCCGGAGCACTAAAATCTCCCCCGGGATCTAGACC-3′(SEQ ID NO: 32) KD3-259 5′-GGTCTAGATCCCGGGGGAGATTTTAGTGCTCCGGCTCC-3′

The resulting construct was named pCMB030.

A R39K mutated neublastin was formed by replacement of arginine at aminoacid 39 with lysine in the neublastin coding sequence of pCMB020.Site-directed mutagenesis of pCMB020 was performed usingoligonucleotides KD3-256 and KD3-257:

(SEQ ID NO: 33) KD3-256 5′-GACGAATTAATTAAGTTTCGTTTTTGTTCAGG-3′ (SEQ IDNO: 34) KD3-257 5′-CCTGAACAAAAACGAAACTTAATTAATTCGTC-3′

Expression and Characterization of Mutated Neublastin in E. coli

For expression and purification, a plasmid encoding the rat neublastinN95K polypeptide was expressed in E. coli as a His-tagged fusion proteinwith an enterokinase cleavage site immediately adjacent to the start ofthe mature 113 amino acid neublastin sequence. The E. coli was grown ina 500 L fermentor and frozen cell paste was provided. The E. coli cellswere lysed in a APV Gaulin Press and the rat neublastin N95K recoveredfrom the insoluble washed pellet fraction.

The N95K mutated neublastin was extracted from the pellet with guanidinehydrochloride, refolded, and the His-tag removed with enterokinase (seeExample 5). The product was then subjected to chromatography on Ni NTAagarose (Qiagen) and on Bakerbond WP CBX cation exchange resin.

Enterokinase treatment of the His tagged product resulted in an aberrantcleavage of the protein at arginine 7 in the mature sequence. Theresulting des 1-7 neublastin product (NBN106-N95K) was fully active inthe KIRA ELISA and structurally indistinguishable from the mature formin its susceptibility to guanidine-induced denaturation and thereforewas used for subsequent work.

Rat mutated neublastin NBN106-N95K was PEGylated at an average of 3.3PEG moieties per neublastin molecule using methoxylpoly(ethyleneglycol)-succinimidyl propionate (SPA-PEG) with a molecular mass of10,000 Da as the reactant. The resulting PEGylated product was subjectedto extensive characterization including analysis by SDS-PAGE, sizeexclusion chromatography (SEC), reverse phase HPLC, matrix assistedlaser desorption/ionization mass spectrometry (MALD/IMS), peptidemapping, assessment of activity in the KIRA ELISA, and determination ofendotoxin content. The purity of the neublastin N95K product prior toPEGylation as measured by SDS-PAGE and SEC was greater than 95%. Theneublastin N95K product migrated under nonreducing conditions as adimer, consistent with its predicted structure. After PEGylation, theresulting product consisted of a series of modified adducts comprising 2PEGs per molecule, which was 5% of the product, 3 PEGs per molecule,which was 60% of the product, 4 PEGs per molecule, which was 30% of theproduct, and several minor forms of higher mass. In the PEGylated samplethere was no evidence of aggregates. Residual levels of unmodifiedneublastin in the product were below the limits of quantitation. Theendotoxin content of the material is routinely less than 1 EU/mg. Thespecific activity of the PEGylated neublastin in the KIRA ELISA is 10nM. The PEGylated product was formulated at 1.1 mg/mL in PBS pH 6.5. Thematerial, which is similar in potency to wild-type neublastin (NBN113),can be supplied as a frozen liquid, which is stored at −70° C.

The R14K, R39K, and R68K mutated neublastin polypeptides were expressedin E. coli and can be subjected to the same methods for purification,PEGylation and assessment of function as described above for theNBN106-N95K neublastin.

Preparation of PEGylated Mutated Neublastin NBN106-N95K

230 mL of the refolded rat N95K mutated neublastin (2.6 mg/mL) that hadbeen produced in E. coli and stored at 4° C. in 5 mM sodium phosphate pH6.5, 100 mM NaCl was diluted with 77 mL of water, 14.4 mL of 1M HEPESpH7.5, and 2.8 g (10 mg/mL final) of PEG SPA 10,000 Da (ShearwaterPolymers, Inc.). The sample was incubated at room temperature for 4hours in the dark, then treated with 5 mM imidazole (final), filtered,and stored overnight at 4° C. The product was generated in two batchesone containing 130 mL of the N95K bulk and the other containing 100 mLof the bulk. The PEGylated neublastin was purified from the reactionmixture on Fractogel EMD S0₃ ⁻(M) (EM Industries). The column was run atroom temperature. All buffers were prepared pyrogen free. Sodiumchloride was added to the reaction mixture to a final concentration of87 mM and the sample was loaded onto a 45 mL Fractogel column (5 cminternal diameter).

The column was washed with one column volume of 5 mM sodium phosphate pH6.5, 80 mM NaCl, then with three one column volume aliquots of 5 mMsodium phosphate containing 50 mM NaCl. The resin was transferred into a2.5 cm diameter column and the PEGylated neublastin was eluted from thecolumn with six ten mL steps containing 5 mM sodium phosphate pH 6.5,400 mM NaCl, three steps containing 500 mL NaCl, and six stepscontaining 600 mM NaCl. Elution fractions were analyzed for proteincontent by absorbance at 280 nm and then for extent of modification bySDS-PAGE. Selected fractions were pooled, filtered through a 0.2 μmfilter, and diluted with water to 1.1 mg PEGylated rat neublastin/mL.After assessing endotoxin levels in the individual batches, they werepooled and refiltered through a 0.2 μm membrane. The final material wasaliquoted and stored at −70° C.

UV Spectrum of Purified PEGylated Mutated Neublastin NBN106-N95K

The UV spectrum (240-340 nm) of PEGylated NBN N95K was taken on the neatsample. The sample was analyzed in triplicate. The PEGylated sampleexhibited an absorbance maximum at 275-277 nm and an absorbance minimumat 247-249. This result is consistent with what is observed on the bulkintermediate. The protein concentration of the PEGylated product wasestimated from the spectrum using an extinction coefficient of Σ₂₈₀^(0.1%)=0.50. The protein concentration of the PEGylated neublastin bulkis 1.1 mg/mL. No turbidity was present in the sample as evident by thelack of absorbance at 320 nm.

Characterization of PEGylated Mutated Neublastin NBN106-N95K by SDS-PAGE

Aliquots of PEGylated neublastin containing 3, 1.5, 0.75, and 0.3 μg ofthe product were subjected to SDS-PAGE on a 4-20% gradient gel (Owl).The gel was stained with Coomassie brilliant blue R-250. Molecularweight markers (GIBCO-BRL) were run in parallel.

SDS-PAGE analysis of PEGylated mutated neublastin NBN106-N95K under nonreducing conditions revealed a series of bands corresponding tomodifications with 2, 3, 4, and more than 4 PEGs per molecule. The majorband with apparent mass of 98 kDa contains 3 PEGs per molecules. In thepurified PEGylated product, non-PEGylated neublastin was not detected.The presence of a mixture of products with 2, 3 and 4 PEGS attached wasverified by MALDI mass spectrometric analysis. The ratio of productcontaining 2, 3, and 4 PEGs was determined by densitometry anddetermined to be 7, 62, and 30 percent of the total, respectively.

Characterization of PEGylated Mutated Neublastin NBN106-N95K By SizeExclusion Chromatography

PEGylated mutated neublastin NBN106-N95K was subjected to size exclusionchromatography on an analytical Superose 6 HR1O/30 FPLC column using 5mM MES pH 6.5, 300 mM NaCl as the mobile phase. The column was run at 20mL/h. Elution fractions were monitored for absorbance at 280 nm. ThePEGylated mutated neublastin eluted as a single peak with an apparentmolecular weight of about 200 kDa consistent with the large hydrodynamicvolume of the PEG. No evidence of aggregates was observed. Freeneublastin, which elutes with an apparent molecular mass of about 30kDa, was not detected in the preparation.

Analysis of PEGylated Mutated Neublastin NBN106-N95K by Reverse PhaseHPLC

PEGylated mutated neublastin NBN106-N95K was subjected to reverse phaseHPLC on a Vydac C₄ (5 μm, 1×250 mm) column. The column was developedusing a 60 mm gradient from 40 to 60% B (Buffer A: 0.1% TFA, Buffer B:75% acetonitrile/0.085% TFA). The column effluent was monitored forabsorbance at 214 nm and fractions collected for subsequent analysis.PEGylated NBN106-N95K was fractionated into its various di (60.5 mm),tri (63.3 mm), and tetra (67.8 mm) PEGylated components by reverse phaseHPLC on a C₄ column. The relative intensities of the peaks suggest thatthe ratios of the components are 5.4, 60.5, and 30.1%, respectively.Peak identities were verified by MALDI-MS. There was no evidence ofnon-PEGylated NBN106-N95K (elutes at 5-15 mm) in the product.

Analysis of PEGylated Mutated Neublastin NBN106-N95K by MassSpectrometry

PEGylated mutated neublastin NBN106-N95K was desalted on a C₄ Zip Tipand analyzed by mass spectrometry on a Voyager-DE™ STR (PerSeptiveBiosystems) matrix-assisted laser desorption/ionization time-of-flight(MALDI-TOF) mass spectrometer using sinapinic acid as a matrix. 0.5 μLof the purified protein was mixed with 0.5 μL of matrix on the targetplate. Mass spectrometry of PEGylated mutated neublastin NBN106-N95Krevealed singly and doubly charged forms of three adducts. The observedmasses of 43803 Da, 54046 Da, and 64438 Da are consistent withmodifications of 2, 3, and 4 PEGs per molecule.

Analysis of PEGylated Mutated Neublastin NBN106-N95K by Peptide Mapping

The specificity of the PEGylation reaction was evaluated by peptidemapping. PEGylated neublastin was separated into di, tri, and tetraPEGylated components, which were then reduced, alkylated, and furtherseparated into their single chain components by HPLC on a C₄ column.These components and reduced and alkylated non-PEGylated NBN106-N95K asa control were digested with Asp-N proteinase and the resulting cleavageproducts were fractionated by reversed phase HPLC on a Vydac C₁₈ (5 μm,1×250 mm) column using a 60 mm gradient from 0 to 60% B (Buffer A: 0.1%TFA, Buffer B: 75% acetonitrile/0.085% TFA). The column effluent wasmonitored for absorbance at 214 mm.

The rat neublastin sequence contains five internal aspartic acids andtherefore was expected to yield a simple cleavage profile when digestedwith endoproteinase Asp-N. All of the peaks from the Asp-N digest of ratN95K have been identified by mass spectrometry and/or Edmanamino-terminal sequencing and thus the peptide map can be used as asimple tool to probe for the sites of modification by the presence orabsence of a peak. The identity of the various peaks are summarizedbelow in Table 7.

TABLE 7 Observed Theoretical Residue Peak by Retention Mass MassAssignment Time (mm) Average Average (SEQ ID NO:2) Amino Acid Sequence38.8 1261.1 (M) 1262.4 102-113 DHLSATACGCLG 40.7 1090.9 1092.2  93-101DVKSTWRTV 44.6 2508.4 2508.9  35-54 DELIRFRFCSGSCRRARSPH 46.0 2437.02437.8  12-34 DARGCRLRSQLVPVSALGLGHSS 51.4 3456.7 3456.0  55-86DLSLAS...CRPTRY 51.9 4134.4  55-92(oxid) DLSLAS...CRPTRYEAVSFM 53.24136.3 * 4120.8  55-92 DLSLAS...CRPTRYEAVSFM (M) monolostopic mass * dueto oxidation of methionine containing peptide on MALDI.

Since neublastin naturally exists as a homodimer, the rat mutatedneublastin NBN106-N95K product contains four potential sites forPEGylation, the two amino-terminal amines from each of the chains andthe two N95K sites that were engineered into the construct. In thepeptide map of the di-PEGylated chain, only the peak that contains thepeptide with the N95K mutation was altered by the PEG modification. Noneof the other peaks were affected by the PEG modification. The mappingdata therefore indicate that the PEG moiety is specifically attached tothis peptide and not to any of the other peptides that were screened.The second potential site of attachment, the amino-terminus is on apeptide that is only three amino acids long and is not detected in thepeptide map. It is inferred that additional PEG attachments are at thissite. Consistent with this notion, a small percentage of the rat mutatedneublastin N95K is not truncated and contains the mature Ala-1 sequence.This peptide elutes at 30 μm and is visible in the peptide map from thenon-PEGylated digest, but is absent from the PEGylated mutatedneublastin NBN106-N95K digests.

Example 3 Assessing the Potency of Internally PEGylated MutatedNeublastin NBN106-N95K in a Kinase Receptor Activation (KIRA) ELISA

The potency of PEGylated mutated rat neublastin was measured usingneublastin dependent activation/phosphorylation of c-Ret as a reporterfor neublastin activity in an ELISA that was specific for the presenceof phosphorylated RET. NB41A3-mRL3 cells, an adherent murineneuroblastoma cell line which expresses Ret and GFRα3, were plated at2×10⁵ cells per well in 24-well plates in Dulbecco's modified eaglemedium (DMEM), supplemented with 10% fetal bovine serum, and culturedfor 18 h at 37° C. and 5% CO₂.

The cells were washed with PBS, and treated with serial dilutions ofneublastin in 0.25 mL of DMEM for 10 min at 37° C. and 5% CO₂. Eachsample was analyzed in duplicate. The cells were washed with 1 mL ofPBS, and lysed for 1 h at 4° C. with 0.30 mL of 10 mM Tris HCl, pH 8.0,0.5% Nonidet P40, 0.2% sodium deoxycholate, 50 mM NaF, 0.1 mM Na₃ VO₄, 1mM phenylmethylsulfonyl fluoride with gently rocking the plates. Thelysates were further agitated by repeated pipetting and 0.25 mL ofsample was transferred to a 96-well ELISA plate that had been coatedwith 5 μg/mL of anti-Ret mAb (AA.GE7.3) in 50 mM carbonate buffer, pH9.6 at 4° C. for 18 h, and blocked at room temperature for one hour withblock buffer (20 mM Tris HCl pH 7.5, 150 mM NaCl, 0.1% Tween-20 (TBST)containing 1% normal mouse serum and 3% bovine serum albumin).

After a 2 h incubation at room temperature, the wells were washed6-times with TBST. Phosphorylated Ret was detected by incubating thewells at room temperature for 2 h with 2 μg/mL of horseradish peroxidase(HRP)-conjugated anti-phosphotyrosine 4G10 antibody in block buffer,washing 6-times with TBST, and measuring HRP activity at 450 nm with acolorometric detection reagent. The absorbance values from wells treatedwith lysate or with lysis buffer were measured and the backgroundcorrected signal was plotted as a function of the concentration ofneublastin present in the activation mixture. The potency of PEGylatedmutated neublastin (3(,4)×10 kDa PEG NBN106-N95K) in the KIRA ELISA wasindistinguishable from that of the wild-type NBN113 material (Table 8).There was no effect of two freeze-thaw cycles on potency and followingthis treatment there was no significant increase in the turbidity of thesample, indicating that the samples can be safely thawed for the study.In independent studies accessing the activity of product with three andfour 10 kDa PEGs per molecule separately, it was determined that theadduct with three PEGs was fully active, while the four PEG product hadreduced potency (Table 8). These data demonstrate that 3,(4)×10 kDa PEGNBN106-N95K and 3×10 kDa PEG NBN106-N95K is activate Ret to a similarextent and with the same dose-dependence as non-mutated (wild-type)neublastin, NBN113. However, although 4×10 kDa PEG NBN106-N95K activatesRet to a similar extent as non-mutated (wild-type) NBN113, 4×10 kDa PEGNBN106-N95K is approximately 10-fold less potent than non-mutated(wild-type) NBN113 in activating Ret. Estimated EC50's are provided inTable 8.

Example 4 Pharmokinetic Studies of Internally PEGylated Mutated RatNeublastin NBN106-N95K in Rats and Mice

The pharmokinetic properties of various PEGylated and non-PEGylatedmutated neublastin products in rat and mouse models were examined (seeTable 8 for summary of results).

The data revealed that PEGylation of rat mutated neublastin NBN1 06-N95Kwith 3.3, 10000 Da PEGs resulted in a significant effect on the halflife and bioavailability of the neublastin. Following a 1 mg/kg IVadministration in Sprague Dawley rats, peak levels of PEGylated mutatedneublastin of 3000 ng/mL were detected after 7 minutes, and levels of700 ng/mL were detected after 24 h, 200 ng/mL after 48 h, and 100 ng/mLafter 72 h. In contrast for non-PEGylated mutated neublastin N95Kfollowing a 1 mg/kg IV administration, levels of 1500 ng/mL weredetected after 7 minutes, but then the levels quickly dropped to 70ng/mL after 3 h and were not detectable after 7 h. The effects ofPEGylation were even more pronounced in animals treated with PEGylatedneublastin by subcutaneous administration.

Following a 1 mg/kg s.c. administration, circulating levels of PEGylatedneublastin reached a maximum of 200 ng/mL after 24 h and remained atthis level for the duration of the three day study. In contrast, nodetectable neublastin was observed at any time point followingadministration of non-PEGylated mutated neublastin.

The analysis of the PEGylated N95K samples are complicated by thepresence of adducts comprising 2, 3 and 4 PEGs per molecule, which eachwill display a different PK profile. In early PK studies, mice were usedto facilitate screening through a variety of candidates and routes ofadministration. The mouse studies revealed dramatic differences in thebioavailability of the candidates. However, when the 3.3 10 kDa PEGadduct was evaluated in rats, it was found to be less bioavailable inrats than it was in mice. This difference in bioavailability wasparticularly pronounced following i.p. administration. Levels in micereached 1600 ng/mL after 7 hr and remained at 400 ng/mL after 24 hr. Incontrast, rat levels were constant at 100 ng/mL for 4-48 hr.

Two surprising and unexpected results emerged from the PK studiessummarized in Table 8: 1) PEGylation of the amino-terminal amino acidsof non-glycosylated neublastin was not sufficient to increase serumexposure substantially; and 2) PEGylation of the amino-terminal aminoacid(s) of neublastin together with modification (e.g. PEGylation orglycosylation) of amino acid 95 was sufficient to increase serumexposure substantially. For example, glycosylated NBN104 (CHO) gave nodetectable exposure after s.c. administration; however, glycosylated1×20 kDa PEG NBN104 (CHO) gave high serum exposure after s.c.administration. Similarly, 2×20 kDa PEG NBN113 gave low-to-moderateserum exposure after s.c. administration; however, glycosylated 2×20 kDaPEG NBN104 (CHO) gave high serum exposure after s.c. administration.These results indicated that polymer conjugation of the amino-terminalamino acid(s) of neublastin together with either polymer conjuation ofan internal amino acid (e.g. at position 95) or glycosylation at aninternal amino acid (e.g. at position 95) results in substantiallyincreased serum exposure after systemic administration.

Both wild-type rat neublastin and mutated neublastin N95K were refoldedand purified to >95% for efficacy tests in the STZ diabetic ratneuropathy model. Wild-type neublastin was formulated to go directlyinto animal testing while N95K was prepared for PEGylation with 10 kDaPEG-SPA. To accomplish the refolding and purification goal, a refoldingmethod utilizing size exclusion chromatography (SEC) was developed thatpermitted the renaturation of neublastin from E. coli inclusion bodiesin large quantities and at high concentrations. In addition to SEC, bothNi-NTA and CM silica column chromatography steps were employed toincrease the final protein purity. The proteins were subjected toextensive characterization including analysis by SDS-PAGE, sizeexclusion chromatography, ESMS, assessment of activity by KIRA ELISA,and determination of endotoxin content. SDS-PAGE and SEC of the finalprotein products indicated a purity of greater than 95%. The endotoxinlevel of each product was <0.2 EU/mg. The specific activity of bothproteins in the KIRA ELISA is approximately 10 nM. Wild-type neublastinwas formulated at 1.0 mg/ml and N95K was formulated at 2.6 mg/ml inphosphate-buffered saline (PBS) pH6.5. Wild-type neublastin wasaliquoted into 15 ml tubes and stored frozen at −70° C. while N95K wassubjected to PEGylation prior to aliquoting and freezing.

Example 5 Refolding and Purification of a Wild-Type Neublastin and theMutated N95K Neublastin

Both neublastin forms were expressed in E. coli as Histidine(His)-tagged fusion proteins with an enterokinase cleavage siteimmediately adjacent to the start of the mature 113 amino acid sequence.Bacteria expressing either wild-type (1.8 kg pellet) or N95K (2.5 kgpellet) neublastin were subjected to lysis in 2 liters of PBS using aAPV Gaulin Press. Following centrifugation (10,000 rpm) to pellet theinclusion bodies, the supernatants from each preparation were discarded.The inclusion body pellets were washed two times with wash buffer (0.02MTris-HCl pH 8.5, 0.5 mM EDTA) then washed two times with the same buffercontaining Triton X-100 (2%, v/v) followed by two additional bufferwashes without detergent. Both pellets were solubilized using 6Mguanidine hydrochloride, 0.1M Tris pH 8.5, 0.1M DTT, and 1 mM EDTA. Toaid in the solubilization process, each pellet was subjected tohomogenization using a polytron homogenizer followed by overnightstirring at room temperature. The solubilized proteins were clarified bycentrifugation prior to denaturing chromatography through Superdex 200(5.5 liter column equilibrated with 0.05M glycine/H₃P0₄ pH 3.0 with 2MGuanidine-HCl) at 20 ml per minute.

Denatured neublastin was identified by SDS-PAGE. Fractions containingeither wild type-neublastin or N95K were pooled and concentrated toapproximately 250 mL using an Amicon 2.5-liter stirred cellconcentrator. After filtration to remove any precipitate, theconcentrated protein was subjected to renaturing sizing chromatographythrough Superdex 200 equilibrated with 0.1 M Tris-HCl pH 7.8, 0.5Mguanidine-HCl, 8.8 mM reduced glutathione and 0.22 mM oxidizedglutathione. The column was developed using 0.5M guanidine-HCl at 20 mLper minute. Fractions containing renatured wild-type neublastin or N95Kneublastin were identified by SDS-PAGE, pooled, and stored at 4° C.until needed for His tag removal.

Alternative Method of Refolding Wild-Type Neublastin and Mutated N95KNeublastin by Dilution.

To refold neublastin by dilution, solubilzed protein was rapidly dilutedin refolding buffer (0.5 M guanidine-HCl, 0.35 M L-Arginine, 50 mMpotassium phosphate (pH 7.8), 0.2 mM glutathione reduced, 1 mMglutathione oxidized, and 0.1% Tween-80) at a final concentration of 0.1mg/ml and incubated at room temperature for 48 hours without stirring.Refolded neublastin was then concentrated 25 fold, brought to 40 mMimidazole, and applied to a chromatography column containing Ni-NTAagarose to further concentrate the product and eliminate host cellproteins. The column was washed with 10 times column volume with washbuffer (40 mM imidazole, 0.5 M guanidine-HCl). Neublastin was theneluted from the resin with 0.2 M Imidazole and 0.5 M guanidine-HCl.

Concentration of Column-Refolded Neublastin by Ni-NTA Chromatography.

Column-renatured neublastin was stored at 4° C. for at least 24 hoursbefore proceeding with the purification to promote disulfide formationbetween the neublastin monomers. During this time, a precipitate formedand was removed by filtration through a 0.2μ polyether sulfone (PES)filter unit. To decrease non-specific binding, the protein solution wasbrought to 20 mM imidazole prior to loading on a 100 ml Ni-NTA (Qiagen)column equilibrated with column buffer (0.5 M guanidine and 20 mMimidazole) at 50 ml per minute. Following the protein application, thecolumn was washed to baseline using the same buffer. Neublastin waseluted from the resin using approximately 300 mL of elution buffercontaining 0.5 M guanidine-HCl and 0.4 M imidazole. After elution,neublastin was dialyzed overnight (using 10 kDa dialysis tubing) at roomtemperature against ten volumes of 5 mM HCl. Dialysis promotes thehydrolysis of contaminating substances and decreases the guanidine-HCland imidazole concentrations to 0.05M and 0.04M, respectively.

Cleavage of the His Tag by Lysyl Endopeptidase or Enterokinase.

The next day, any precipitate that formed during dialysis was removed byfiltration. The following purification steps apply to both the column-and dilution-refolded neublastin products. The protein sample was madeto 0.1 M NaCl by the addition of NaCl from a 5M stock for a final saltconcentration including the remaining guanidine-HCl of approximately 150mM. This concentration was confirmed using a conductivity meter.Additionally, 1 M HEPES pH 7.8 was added for a final concentration of 25mM. To cleave the His tag, lysyl endopeptidase was added to thewild-type neublastin and enterokinase was added to the N95K mutatedneublastin, both at an approximately 1:300 ratio of protease toneublastin. Enterokinase was used in place of lysyl endopeptidase forthe N95K mutated neublastin due to an additional protease cleavage sitein the mutated protein at Lys95. The samples were stirred at roomtemperature for 2 hours and the digestions monitored by SDS-PAGE.

His Tag Removal by Ni-NTA Chromatography.

Protease-treated neublastin was applied to a 100 mL Ni-NTA columnequilibrated with 0.5M guanidine-HCl and 20 mM imidazole at 50 mL perminute. The column was washed to baseline with the same buffer. Anyprotein washing off the column was pooled with the flow-through proteincontaining neublastin without the His tag.

CM Silica Chromatography.

Following Ni-NTA chromatography, the protein was immediately subjectedto further purification through CM silica resin. A 20 mL CM silicacolumn equilibrated with loading buffer (5 mM phosphate pH 6.5, 150 mMNaCl) was loaded with neublastin at 20 mL per minute. The column waswashed with twenty column volumes of wash buffer (5 mM phosphate pH 6.5,400 mM NaCl) and the protein step eluted with elution buffer containing5 mM phosphate pH 6.5 but with 1 M NaCl. The eluted protein was dialyzedovernight against the phosphate alone to bring the salt concentrationdown to 100 mM for N95K and 150 mM for wild type neublastin. Bothsamples were filtered through a 0.2μ PES filter unit, analyzed bySDS-PAGE, and stored at 4° C. until needed for further characterizationsand/or PEGylation.

Wild-type and N95K mutated neublastin protein preparations weresubjected to UV spectrum analysis to assess their absorbance at 280.Using a micro quartz cuvette and blanking against buffer alone, 100 μlof either wild-type or N95K mutated neublastin was continuously scannedfrom 230 to 330 nm using a Beckman spectrophotometer. Based on thisanalysis, wild-type neublastin was determined to be at a concentrationof 1.1 mg/ml and N95K mutated neublastin at 2.6 mg/ml (A280nm-E^(0.1%)=0.5 used for each protein). Less than 1% precipitatedmaterial was identified based on absorbance at 330 nm.

To assess the purity of both protein preparations, each sample (0.5 mg)was subjected to size exclusion chromatography through a 16/30 Superdex75 column. The column was equilibrated with 5 mM phosphate pH 6.5containing 400 mM NaCl and developed with a 1.5 mL per minute flow rate.Based on the absorbance at 280 nm, both wild-type and N95K mutatedneublastin preparations migrated as a single peak with an expectedmolecular weight (23-24 kDa), and they did not contain any significantprotein contamination.

Both wild-type and N95K mutated neublastin proteins were reduced in 2.5M guanidine-HCl, 60 mM Tris pH 8.0 and 16 mM DTT. The reduced sampleswere desalted over a short C₄ column and analyzed on-line by ESMS usinga triple quadrupole instrument. The ESMS raw data were deconvoluted bythe MaxEnt program to generate mass spectra. This procedure allowsmultiple charged signals to collapse into one peak that directlycorresponds to the molecular mass in kilodaltons (kDa). The deconvolutedmass spectrum for wild-type showed the predominant species is 12046 Da,which is in agreement with the predicted molecular weight of 12046.7 Dafor the 113 amino acid form of the protein. A minor component was alsoobserved (12063 Da) suggesting the presence of an oxidation product.Three peaks were identified in the N95K mutated neublastin proteinsample. The major component demonstrated an apparent molecular mass of11345 Da in agreement with the predicted mass for the 106 amino acidform of the protein. The other two peaks had masses of 11362 and 12061Da, suggesting N95K oxidation and the presence of the 113 amino acidform, respectively.

The presence of the 106 and 113 amino acid forms in the N95K mutatedneublastin protein preparation is attributable to digestion withenterokinase. This protease from Biozyme is a natural enzyme preparationpurified from calf intestinal mucosa and is reported to contain a slighttrypsin contamination (0.25 ng trypsin per μg enterokinase). Therefore,trypsin may be acting on the N95K mutated neublastin protein on thecarboxy terminal side of Arg7 to produce the predominant 106 amino acidform. On the other hand, lysyl endopeptidase used to cleave wild-typeneublastin is a single protease activity acting on the carboxy terminalside of the lysine residue contained within the His tag to produce themature 113 amino acid neublastin form. Both the 106 and 113 amino acidforms of neublastin are equally active in all assays tested and behavesimilarly in guanidine-HCl stability tests.

Neublastin activity was determined by its ability to stimulate c-Retphosphorylation in NB41A3-mRL3 cells using the KIRA ELISA described inExample 3. Phosphorylated Ret was detected by incubating (2 hours) thecaptured receptor with HRP-conjugated phosphotyrosine antibody (4G10;0.2 μg per well). Following the incubation, the wells were washed sixtimes with TBST, and the HRP activity detected at 450 nm with acolorimetric assay. The absorbance values from wells treated with lysateor with lysis buffer alone were measured, background corrected, and thedata plotted as a function of the concentration of neublastin present inthe activation mixture. The data demonstrate that the purifiedneublastin polypeptides resulted in the appearance of phosphorylatedRET, indicating that the purified neublastin was active in this assay.

Example 6 Preparation of a Serum Albumin-Neublastin Conjugate

Wild-type rat neublastin at a concentration of 1 mg/ml in PBS wastreated with 1 mM sulfo-SMCC (Pierce) and desalted to remove excesscross-linker. Since the wild-type neublastin protein contains only asingle amine at its amino-terminus and no free sulfhydryl groups,reaction with SMCC was expected to result in site-specific modificationof the neublastin with SMCC attached at its amino-terminus.

Next, 60 μg of the neublastin-SMCC conjugate was incubated with 120 μgof bovine serum albumin and analyzed for extent of cross-linking bySDS-PAGE. BSA contains a single free SH group and consequently reactionwith the neublastin-SMCC conjugate is expected to result in modificationat this site through the maleimide on the SMCC. Under these conditions,two additional bands of higher molecular weight were observed, which areconsistent in mass with modification of the neublastin with a single BSAmoiety and with two BSA molecules since each neublastin moleculecontains two amino-termini that can undergo reaction, and consequentlyare in agreement with this notion. Concurrent with the formation ofthese bands, was a decrease in the intensity of the neublastin-SMCC andBSA bands. Based on the intensity of the remaining neublastin band, thereaction appeared to have gone to 70-80% completion.

The monosubstituted product was purified from the reaction mixture bysubjecting the material to cation exchange chromatography and sizeexclusion chromatography on a Superdex 200 column (Pharmacia)essentially as described for PEGylation studies discussed above. Columnfractions from the gel filtration run were analyzed by SDS-PAGE andthose containing the monosubstituted product were analyzed for proteincontent by absorbance at 280 nm. Since the mass of BSA is approximatelytwice that of neublastin, the apparent concentration was divided by afactor of 3 to give the neublastin equivalent. This fraction wassubjected this to analysis for function in the KIRA ELISA. IC50 valuesfor both the wt- and BSA-conjugated neublastin were 3-6 nM, indicatingthat conjugation to the BSA had not compromised function.

While these preliminary studies were generated with BSA, thecorresponding serum albumin proteins from rats and humans also contain afree SH. Consequently a similar approach can be applied to generate arat serum albumin-rat neublastin conjugate for performing PK andefficacy studies in rats and human serum albumin-human neublastin forperforming clinical trials. Similarly SMCC can be substituted with anyof a number of cross-linkers that contain an amino reactive group on oneside and a thiol reactive group on the other side. Examples of aminereactive cross-linkers that insert a thiol reactive-maleimide are AMAS,BMPS, MBS, EMCS, SMPB, SMPH, KMUS, or GMBS, that insert a thiolreactive-haloacetate group are SBAP, SIA, SIAB and that provide aprotected or non protected thiol for reaction with sulfhydryl groups toproduct a reducible linkage are SPDP, SMPT, SATA, or SATP all of whichare available from Pierce. Such cross linkers are merely exemplary andmany alternative strategies are anticipated for linking theamino-terminus of neublastin with serum albumin. A skilled artisan alsocould generate conjugates to serum albumin that are not targeted at theamino-terminus of neublastin or at the thiol moiety on serum albumin.Neublastin-serum albumin fusions created using genetic engineering whereneublastin is fused to the serum albumin gene at its amino-terminus,carboxy-terminus, or at both ends, are also expected to be functional.

This method can be extended through routine adaptations to anyneublastin-serum albumin conjugate that would result in a product with aprolonged half-life in animals and consequently in humans.

Example 7 Crystallization and Structure Determination of HumanNeublastin

Selenomethionine labeled neublastin was expressed using a standardprocedure to inhibit methionine biosynthesis (Van Duyne, et al., 1991,Science 252, 839-842). Both wildtype neublastin andselenomethionine-incorporated neublastin was concentrated to 17 mg/ml in0.8 M arginine. The protein stock was concentrated to 17 mg/ml in 0.8 Marginine. Crystals were grown by the hanging-drop vapor diffusion method(Jancarik, J. & Kim, S. H., 1991, J. Appl. Crystallogr. 24, 409-411) outof 1.25 M magnesium sulfate, 0.1 M MES pH 6.5 at 20° C. The mostreproducible crystals were obtained by microseeding. The crystals werecryoprotected by the addition of 5% ethylene glycol every 60 seconds toa final concentration of 1.25 M magnesium sulfate, 0.1 M MES pH 6.5, and30% (v/v) ethylene glycol and then frozen by quick transfer into liquidnitrogen.

Crystals approximately 100 microns on each side diffracted to 1.6A atbeamline X4A at the National Synchrotron Light Source (Upton, N.Y.).Data processing with the HKL program package (Otwinowski (1993) in:Proceeding of the CCP4 Study Weekend: Data Collection and Processing(Sawer et al., Eds.) pp. 56-62, Daresbury Laboratory, Warrington)revealed the crystals to belong to a C2 space group with 1 covalentdimer per asymmetric unit and approximate cell dimensions a=115 Å, b=33Å, c=55 Å and α=γ=90°, β=99°.

The crystal structure was solved by multiple isomorphous replacements.Native neublastin crystals were soaked in 1 mM PtCl₄ for 4 hours, 10 mMIrCl₃ for 72 hours, and 10 mM IrCl₆ for 18 hours and data collected andprocessed by the HKL suite (Otwinowski et al., supra). The twoselenomethionine sites were located by inspection of isomorphous andanomalous difference pattersons. The remaining sites were located usingSOLVE (4). The phases were improved by RESOLVE (Terwilliger et al.,1999, Acta Crystallogr. D. 55, 849-861) to a figure of merit of 0.56 andresulting maps were of sufficient quality to trace the neublastin model.Alternating cycles of model building with O2D (5 G J Kleywegt & T AJones, “O2D—the manual”, software manual, Uppsala, 1994) and refinementwith CNX using a mlhl target and refined against the selenomethioninedata resulted in a complete model of the neublastin protein, excludingthe first amino-terminal 13 amino acids, as well as 89 water moleculesand 6 sulfate anions. The final R_(free) is 28.5% and R-factor is 24.7%to 2.0 Å with good stereochemistry.

Example 8 Sulfate Binding Sites and Modeling of Heparin Sulfate

A cluster of three sulfates at the vertices of an approximateequilateral triangle are located on at the pre-helix region of theneublastin surface and could represent a binding site for heparinsulfate. There are three arginine residues that appear to have keyinteractions with these sulfates. The arginine residue R48 linkstogether all three sulfates (#2, #6, and #3). Its backbone amideinteracts with sulfate #2, while its side chain guanidinium group formsa bifurcated hydrogen bond with sulfates #6 and #3. A second arginineresidue (R49) forms a hydrogen bond with sulfate #2 and a third arginineresidue (R51) forms a long hydrogen bond to sulfate #6.

These sulfates may represent binding pockets for heparin sulfate, whichif mutated to non-positively charged residues could reduce heparinsulfate binding and possibly decrease and/or delay clearance of theneublastin molecule upon in vivo administration. A model of heparinsulfate bound to neublastin may be constructed by superimposing thesulfates of the glycosaminoglycan with the existing sulfates of theneublastin crystal structure. The n and n+2 saccharide-linked sulfatesin heparin sulfate from the crystal structure of FGF-1 complexed toheparin sulfate are separated by approximately 8.5 Å (Pellegrini et al.,(2000) Nature 407, 1029-1034). This measurement closely matches thedistance between sulfates of the 3-sulfate cluster in the neublastinstructure; sulfates #3 and #6 are separated by 8.8 Å and sulfates #3 and#2 are separated by 8.1 Å. This distance measurement correspondancecould indicate that this R48/R49/R51 motif is part of a heparin bindingsite. This suggests that single site mutations of R48, R49 or R51 toglutamate or aspartate, or any other non-positive amino acid, mightreduce heparin sulfate binding affinity without reducing thereceptor-binding activity of neublastin, thereby resulting in abiologically active product that has a prolonged half-life in animalsand consequently in humans. To test this possibility, we are generatinga series of constructs that contain one or more arginines mutated toglutamic acids. The mutated neublastin products will be expressed in E.coli, purified and refolded, and tested for function. Finally, theproducts will be tested for ability to bind heparin and forpharmacokinetics and pharmacodynamics in animals.

One or more of these sites might also provide other sites for PEGylationwhich can be accomplished by replacing R with K or C and applying themethods described above.

Example 9 Dosage of Pegylated Mutated Neublastin NBN106-N95K on Reversalof Tactile and Thermal Hyperalgesia in Nerve Ligation Animal Model ofNeuropathic Pain

We had previously demonstrated that 1 mg/kg wild-type neublastin,administered s.c. 3 times per week, results in nearly complete reversaland normalization of neuropathic pain behaviors (tactile allodynia andthermal hyperalgesia) induced by spinal nerve ligation in the rat,whereas 0.03 mg/kg wild-type neublastin, administered s.c. 3 times perweek had no effect and 0.1 mg/kg and 0.6 mg/kg wild-type neublastin,administered s.c. 3 times per week had intermediate effects in thismodel.

Here, we describe studies to address the reversal effect of pegylatedN95K neublastin on tactile allodynia and thermal hyperalgesia in theChung L5/L6 spinal nerve ligation (“SNL”) model. Sprague-Dawley malerats (230-380 g) were divided into two groups. All rats received thespinal nerve ligation. One group of rats (n=6) was administered vehicleby subcutaneous injection. A second group of rats (n=6 per group) wereadministered pegylated N95K neublastin (3,(4)×10 kDa PEG NBN106-N95K) bysubcutaneous injection at 10 μg/kg. 3(,4)×10 kDa PEG NBN106-N95K,comprised neublastin protein that was E. coli-derived and contained anAsn-to-Lys amino acid substitution at position 95, then truncated(amino-terminus truncation of 7 amino acids; NBN106), and finallypegylated with an average of 3.3 PEG moieties per dimer of NBN, usingmethoxylpoly(ethylene glycol)-succinimidyl propionate (SPA-PEG) with amolecular mass of 10,000 Da as the reactant. The vehicle consisted of 5mM phosphate and 150 mM sodium chloride at pH 6.5. Subcutaneousinjections were administered on days 3, 5, 7, 10, 12 and 14 followingthe operation (post-SNL). The Von Frey (Chaplan et al. (1994), J.Neurosci. Meth. 53: 55-63) and Hargreave's (Hargreaves et al. (1988),Pain 32: 77-88) behavioral tests were used to monitor tactile andthermal responses, respectively. These pain responses were monitoredprior to the spinal nerve ligation to establish baseline responses, onday 2 post-SNL to verify the presence of tactile and thermalhyperalgesia, and then on days 3, 5, 7, 10, 12, 14 and 15 post-SNL. Toassess statistical significance of drug treatment relative to vehicletreatment, a 1-way analysis of variance (1-way ANOVA) was carried outfollowed by a post-hoc Student Neuman Keuls (SNK) test.

Both types of neuropathic pain behavior (tactile allodynia and thermalhyperalgesia) developed fully by day 2 post-SNL, as expected.Subcutaneous administration of 10 μg/kg 3(,4)×10 kDa PEG N95K-NBN106 ledto substantial and statistically significant reversal of both types ofneuropathic pain in rats with spinal nerve ligation. In rats with spinalnerve ligation, the effect of 10 μg/kg 3(,4)×10 kDa PEG NBN106-N95K onthermal sensitivity and tactile allodynia first became statisticallysignificant 4 days after the initiation of administration of pegylatedN95K neublastin. The effect of 10 μg/kg 3(,4)×10 kDa PEG NBN106-N95K onthermal sensitivity and tactile allodynia reached a plateauapproximately 4 days after the initiation of administration of pegylatedN95K neublastin. The effects of 3(,4)×10 kDa PEG NBN106-N95K did notdiminish during the 2 to 3 day interval between administrations. Infact, there was substantial normalization of pain behaviors between theadministrations of pegylated N95K neublastin on days 5 and 7. In anotherexperiment (data not shown), subcutaneous administration of 3 μg/kg3(,4)×10 kDa PEG NBN106-N95K on days 3, 5, 7, 10, 12 and 14 led to asignificant normalization of pain behaviors (tactile and thermalhyperalgesia) in the SNL model, though the onset of the effect wassomewhat slower.

These results demonstrated that of 3(,4)×10 kDa PEG NBN106-N95K has anincreased potency of at least 100 to 333-fold over non-mutatednon-glycosylated neublastin on tactile allodynia and thermalhyperalgesia pain behaviors in the SNL model. The enhancedpharmacokinetic properties of 3(,4)×10 kDa PEG N95K NBN106 compared tonon-mutated non-glycosylated neublastin indicated that efficacy ofsystemically administered neublastin correlates with serum levels ofneublastin. These results demonstrated that polymer conjugates ofmutated neublastin can be used to treat neuropathic pain in patientswith greatly reduced doses, and potentially reduced dosing frequency,due to their enhanced bioavailability compared to unconjugatedneublastin.

TABLE 8 Biological Characterization of PEGylated NBN KIRA: Exposure in~Max PEGylated Glycosylated Mice After s.c. KIRA: Efficacy Form of NBNAmino Acids Amino Acid Administration ~EC50 vs WT NBN nd 0.4-1.2 nM   100% NBN104 (CHO) 95, 95 nd 0.7 nM 90% 2 × 5 kDa 1, 1 nd 0.2 nM 105%PEG-NBN 4 × 5 kDa PEG 1, 1, 95, 95 nd   1 nM 80% NBN106-N95K 2 × 10 kDa1, 1 nd 0.2 nM 72% PEG-NBN 1 × 20 kDa 1 nd 0.2 nM 83% Branched PEG-NBN 1× 20 kDa 1 95, 95 ++ 0.3 nM 110% PEG-NBN104 (CHO) 3 × 10 kDa 1, 1, 95 ++0.7 nM 115% PEG-WT/ N95K-NBN106 3 × 10 kDa PEG 1, 1, 95 ++ 0.8 nM 100%NBN106-N95K 3 (,4) × 10 kDa 1, 1, 95 (,95) ++ 1.6 nM 90% PEG NBN106-N95K 4 × 10 kDa PEG 1, 1, 95, 95 ++  11 nM >80% NBN106-N95K 2 × 20 kDa1, 1 + 0.6 nM 80% PEG-NBN 2 × 20 kDa 1, 95 ++ inactive inactive BranchedPEG NBN106-N95K 2 × 20 kDa 1, 1 95, 95 ++   1 nM 105% PEG-NBN104 (CHO)Note: nd denotes not detectable, + indicates low-moderate exposure, ++indicates high exposure Note: all are NBN113, unless otherwise indicatedNote: all are E. coli derived, unless CHO is indicated

SEQ ID NO: Sequence: 1 Consensus mature neublastin polypeptide - 113 aa2 Human mature NBN113 3 Mouse mature NBN113 4 Rat mature NBN113 5PreproNBN - 220 aa 6 Mature NBN140 7 Mature NBN116 8 Truncated NBN112 9Truncated NBN111 10 Truncated NBN110 11 Truncated NBN109 12 TruncatedNBN108 13 Truncated NBN107 14 Truncated NBN106 15 Truncated NBN105 16Truncated NBN104 17 Truncated NBN103 18 Truncated NBN102 19 TruncatedNBN101 20 Truncated NBN100 21 Truncated NBN99 22 Polypeptide DYKDDDD - 8aa 23 NBN113-N95K 24 NBN106-N95K 25 Rat wild-type ORF - 675 nt 26 Ratwild-type preproNBN polypeptide - 224 aa 27 KD2-310 Primer 28 KD2-311Primer 29 KD3-254 Primer 30 KD2-255 Primer 31 KD3-258 Primer 32 KD3-259Primer 33 KD3-256 Primer 34 KD3-257 Primer 35 His-tagged NBN ORF - 414nt 36 His-tagged NBN - 135 aa

Other Embodiments

Although particular embodiments have been disclosed herein in detail,this has been done by way of example for purposes of illustration only,and is not intended to be limiting with respect to the scope of theappended claims, which follow. In particular, it is contemplated by theinventors that various substitutions, alterations, and modifications maybe made to the invention without departing from the spirit and scope ofthe invention as defined by the claims.

1. An isolated polypeptide comprising an amino acid sequence at least90% identical to amino acids 8-113 of SEQ ID NO:1, wherein thepolypeptide includes at least one amino acid substitution selected fromthe group consisting of: (a) an amino acid other than arginine at theposition corresponding to position 14 in SEQ ID NO:1; (b) an amino acidother than arginine at the position corresponding to position 39 in SEQID NO:1; (c) an amino acid other than arginine at the positioncorresponding to position 68 in SEQ ID NO:1; and (d) an amino acid otherthan asparagine at the position corresponding to position 95 in SEQ IDNO:1, wherein the polypeptide, when dimerized, binds to GFRα3.
 2. Thepolypeptide of claim 1, wherein the amino acid at the positioncorresponding to position 95 in SEQ ID NO:1 is an amino acid other thanasparagine.
 3. The polypeptide of claim 1, wherein the amino acid at theposition corresponding to position 95 in SEQ ID NO:1 is lysine.
 4. Thepolypeptide of claim 1, wherein the polypeptide comprises amino acids8-113 of SEQ ID NO:2, SEQ ID NO:3, or SEQ ID NO:4, wherein an amino acidother than asparagine is substituted for the asparagine at position 95.5. The polypeptide of claim 1, wherein the polypeptide comprises aminoacids 1-113 of SEQ ID NO:2, SEQ ID NO:3 or SEQ ID NO:4, wherein lysineis substituted for asparagine at position
 95. 6. The polypeptide ofclaim 1, wherein the amino acid sequence is at least 95% identical toamino acids 8-113 of SEQ ID NO:1.
 7. The polypeptide of claim 1, whereinthe amino acid sequence is at least 95% identical to amino acids 8-113of SEQ ID NO:2.
 8. The polypeptide of claim 2, wherein the amino acidsequence is at least 95% identical to amino acids 8-113 of SEQ ID NO:2.9. The polypeptide of claim 3, wherein the amino acid sequence is atleast 95% identical to amino acids 8-113 of SEQ ID NO:2.
 10. A fusionprotein comprising the polypeptide of claim 1 fused to a second moiety.11. The fusion protein of claim 10, wherein the second moiety is a humanserum albumin sequence.
 12. A dimer comprising two polypeptidesaccording to claim
 1. 13. A dimer comprising two fusion proteinsaccording to claim
 10. 14. A conjugate comprising the polypeptide ofclaim 1 conjugated to a non-naturally occurring polymer.
 15. A conjugatecomprising the polypeptide of claim 7 conjugated to a non-naturallyoccurring polymer.
 16. A conjugate comprising the polypeptide of claim 8conjugated to a non-naturally occurring polymer.
 17. A conjugatecomprising the polypeptide of claim 9 conjugated to a non-naturallyoccurring polymer.
 18. A conjugate comprising the fusion protein ofclaim 10 conjugated to a non-naturally occurring polymer.
 19. Theconjugate of claim 14, wherein the polymer is a polyalkylene glycol. 20.The conjugate of claim 19, wherein the polyalkylene glycol ispolyethylene glycol.
 21. The conjugate of claim 15, wherein the polymeris a polyalkylene glycol.
 22. The conjugate of claim 21, wherein thepolyalkylene glycol is polyethylene glycol.
 23. The conjugate of claim16, wherein the polymer is a polyalkylene glycol.
 24. The conjugate ofclaim 23, wherein the polyalkylene glycol is polyethylene glycol. 25.The conjugate of claim 17, wherein the polymer is a polyalkylene glycol.26. The conjugate of claim 25, wherein the polyalkylene glycol ispolyethylene glycol.
 27. The conjugate of claim 19, wherein thepolyalkylene glycol is conjugated to a lysine residue substituted at aposition corresponding to position 14, 39, 68, or 95 in SEQ ID NO:1. 28.The conjugate of claim 19, wherein the polyalkylene glycol is conjugatedto the N terminus of the polypeptide.
 29. The conjugate of claim 19,wherein the polypeptide is glycosylated.
 30. A pharmaceuticalcomposition comprising the polypeptide of claim 1 and physiologicallyacceptable vehicle.
 31. A pharmaceutical composition comprising thefusion protein of claim 10 and physiologically acceptable vehicle.
 32. Apharmaceutical composition comprising the conjugate of claim 19 andphysiologically acceptable vehicle.
 33. A polypeptide comprising anamino acid sequence at least 95% identical to amino acids 15-113 of SEQID NO:2 (NBN99), wherein the polypeptide includes at least one aminoacid substitution selected from the group consisting of: (a) an aminoacid other than arginine at the position corresponding to position 39 inSEQ ID NO:2; (b) an amino acid other than arginine at the positioncorresponding to position 68 in SEQ ID NO:2; and (c) an amino acid otherthan asparagine at the position corresponding to position 95 in SEQ IDNO:2, wherein the polypeptide, when dimerized, binds to GFRα3.
 34. Thepolypeptide of claim 33, wherein the amino acid at the positioncorresponding to position 39 in SEQ ID NO:2 is an amino acid other thanarginine.
 35. The polypeptide of claim 33, wherein the amino acid at theposition corresponding to position 39 in SEQ ID NO:2 is lysine.
 36. Thepolypeptide of claim 33, wherein the amino acid at the positioncorresponding to position 68 in SEQ ID NO:2 is an amino acid other thanarginine.
 37. The polypeptide of claim 33, wherein the amino acid at theposition corresponding to position 68 in SEQ ID NO:2 is lysine.
 38. Thepolypeptide of claim 33, wherein the amino acid at the positioncorresponding to position 95 in SEQ ID NO:2 is an amino acid other thanasparagine.
 39. The polypeptide of claim 33, wherein the amino acid atthe position corresponding to position 95 in SEQ ID NO:2 is lysine. 40.The polypeptide of claim 33, wherein the polypeptide comprises aminoacids 15-113 of SEQ ID NO:2 (NBN99), wherein an amino acid other thanasparagine is substituted for the asparagine at position
 95. 41. Thepolypeptide of claim 33, wherein the polypeptide comprises amino acids15-113 of SEQ ID NO:2 (NBN99), wherein lysine is substituted forasparagine at position
 95. 42. A conjugate comprising the polypeptide ofclaim 33 conjugated to a non-naturally occurring polymer.
 43. Aconjugate comprising the polypeptide of claim 34 conjugated to anon-naturally occurring polymer.
 44. A conjugate comprising thepolypeptide of claim 35 conjugated to a non-naturally occurring polymer.45. A conjugate comprising the polypeptide of claim 36 conjugated to anon-naturally occurring polymer.
 46. A conjugate comprising thepolypeptide of claim 37 conjugated to a non-naturally occurring polymer.47. A conjugate comprising the polypeptide of claim 38 conjugated to anon-naturally occurring polymer.
 48. A conjugate comprising thepolypeptide of claim 39 conjugated to a non-naturally occurring polymer.49. A conjugate comprising the polypeptide of claim 40 conjugated to anon-naturally occurring polymer.
 50. A conjugate comprising thepolypeptide of claim 41 conjugated to a non-naturally occurring polymer.51. The conjugate of claim 42, wherein the polymer is a polyalkyleneglycol.
 52. The conjugate of claim 51, wherein the polyalkylene glycolis polyethylene glycol.
 53. The conjugate of claim 43, wherein thepolymer is a polyalkylene glycol.
 54. The conjugate of claim 53, whereinthe polyalkylene glycol is polyethylene glycol.
 55. The conjugate ofclaim 44, wherein the polymer is a polyalkylene glycol.
 56. Theconjugate of claim 55, wherein the polyalkylene glycol is polyethyleneglycol.
 57. The conjugate of claim 45, wherein the polymer is apolyalkylene glycol.
 58. The conjugate of claim 57, wherein thepolyalkylene glycol is polyethylene glycol.
 59. The conjugate of claim46, wherein the polymer is a polyalkylene glycol.
 60. The conjugate ofclaim 9, wherein the polyalkylene glycol is polyethylene glycol.
 61. Theconjugate of claim 47, wherein the polymer is a polyalkylene glycol. 62.The conjugate of claim 61, wherein the polyalkylene glycol ispolyethylene glycol.
 63. The conjugate of claim 48, wherein the polymeris a polyalkylene glycol.
 64. The conjugate of claim 63, wherein thepolyalkylene glycol is polyethylene glycol.
 65. The conjugate of claim49, wherein the polymer is a polyalkylene glycol.
 66. The conjugate ofclaim 65, wherein the polyalkylene glycol is polyethylene glycol. 67.The conjugate of claim 50, wherein the polymer is a polyalkylene glycol.68. The conjugate of claim 67, wherein the polyalkylene glycol ispolyethylene glycol.